NHG-Richtlijnen
NHG-Standaard
M84
4.1
juni 2019
september 2024
K. Hart-vaatstelsel

Richtlijnen diagnostiek

Naar Volledige tekst ›

Anamnese

Naar Volledige tekst ›

Lichamelijk onderzoek

Naar Volledige tekst ›

Aanvullend onderzoek

Naar Volledige tekst ›

Evaluatie en risicoschatting

Naar Volledige tekst ›

Richtlijnen beleid

Naar Volledige tekst ›

Voorlichting

Naar Volledige tekst ›

Niet-medicamenteuze behandeling

Naar Volledige tekst ›

Medicamenteuze behandeling

Naar Volledige tekst ›

Controles

Naar Volledige tekst ›

Verwijzing

Naar Volledige tekst ›

Belangrijkste wijzigingen

Naar Samenvatting ›

Inleiding

Naar Samenvatting ›

Richtlijnen diagnostiek

Naar Samenvatting ›

1.1 Bij wie wordt het risico op hart- en vaatziekten geschat?

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

1.2 Hoe wordt het cardiovasculair risico geschat en wat zijn de behandelimplicaties?

Naar Samenvatting ›

Opstellen van een cardiovasculair risicoprofiel

Naar Samenvatting ›

Risicocategorieën

Naar Samenvatting ›

Gebruik van de SCORE2(-OP)-tabel

Naar Samenvatting ›

Jongere personen: cardiovasculair risico en behandelimplicaties

Naar Samenvatting ›

Ouderen: cardiovasculair risico en behandelimplicaties

Naar Samenvatting ›

Risicocommunicatie en behandelbeslissingen bij patiënten met hart- en vaatziekte of diabetes mellitus

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

1.3 Aanvullende risico-informatie en aandoeningen met een verhoogd cardiovasculair risico

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

Richtlijnen beleid

Naar Samenvatting ›

Niet-medicamenteuze behandeling

Naar Samenvatting ›

2.1 Leefstijladviezen

Naar Samenvatting ›

2.1.1 Gedragsverandering

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

2.1.2 Psychosociale factoren

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

2.1.3 Sedentaire leefstijl en lichamelijke activiteit

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

2.1.4. Roken

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

2.1.5 Voeding

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

2.1.6 Lichaamsgewicht

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›

2.2 Lipiden

Naar Samenvatting ›
Streefwaarden
Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

Welke lipidenverlagende therapie?

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

2.3 Bloeddruk

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

Diagnostiek

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

Aanvullend onderzoek

Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›
Streefwaarden bloeddruk
Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

Medicamenteuze behandeling

Naar Samenvatting ›
Therapieresistentie
Naar Samenvatting ›

Aanbevelingen

Naar Samenvatting ›

3.1 Interventies op populatieniveau

Naar Samenvatting ›

3.2 Interventies op individueel niveau

Naar Samenvatting ›
Aanbevelingen
Naar Samenvatting ›

Bijlagen

Naar Samenvatting ›

Bijlage 1 (Kwetsbare) ouderen

Naar Samenvatting ›

Bijlage 2 Begrippenlijst

Naar Samenvatting ›

Referenties

  1. Piepoli MF, Hoes AW, Agewall S, et al. European guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts). Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis 2016;252:207-74.
  2. Si S, Moss JR, Sullivan TR, et al. Effectiveness of general practice-based health checks: a systematic review and meta-analysis. Br J Gen Pract 2014;64:e47-e53.
  3. Jorgensen T, Jacobsen RK, Toft U, et al. Effect of screening and lifestyle counselling on incidence of ischaemic heart disease in general population: Inter99 randomised trial. BMJ 2014;348:g3617.
  4. Ebrahim S, Taylor F, Ward K, et al. Multiple risk factor interventions for primary prevention of coronary heart disease. Cochrane Database Syst Rev 2011;1:CD001561.
  5. Krogsboll LT, Jorgensen KJ, Gronhoj Larsen C, et al. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev 2012;10:CD009009.
  6. Perk J, De Backer G, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): the Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012;33:1635-701.
  7. National Institute for Health and Care Excellence. Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: National Institute for Health and Care Excellence, 2014.
  8. American Heart Association. Heart-Health Screenings Ga naar bron
  9. Scottish Intercollegiate Guidelines Network. Risk estimation and the prevention of cardiovascular disease. A national clinical guideline. Edinburgh: Scottish Intercollegiate Guidelines Network, 2007.
  10. Reiner Z, Catapano AL, De Backer G, et al. Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
  11. Chamnan P, Simmons RK, Khaw KT, et al. Estimating the population impact of screening strategies for identifying and treating people at high risk of cardiovascular disease: modelling study. BMJ 2010;340:c1693.
  12. Nielsen AD, Videbech P, Gerke O, et al. Population screening for coronary artery calcification does not increase mental distress and the use of psychoactive medication. J Thorac Imaging 2012;27:202-6.
  13. Christensen B, Engberg M, Lauritzen T. No long-term psychological reaction to information about increased risk of coronary heart disease in general practice. Eur J Cardiovasc Prev Rehabil 2004;11:239-43.
  14. Lokkegaard T, Andersen JS, Jacobsen RK, et al. Psychological consequences of screening for cardiovascular risk factors in an unselected general population: results from the Inter99 randomised intervention study. Scand J Public Health 2015;43:102-10.
  15. Jorgensen T, Ladelund S, Borch-Johnsen K, et al. Screening for risk of cardiovascular disease is not associated with mental distress: the Inter99 study. Prev Med 2009;48:242-6.
  16. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42:3227-37.
  17. SCORE2 working group and ESC Cardiovascular risk collaboration. SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. Eur Heart J. 2021;42:2439-54.
  18. SCORE2-OP working group and ESC Cardiovascular risk collaboration. SCORE2-OP risk prediction algorithms: estimating incident cardiovascular event risk in older persons in four geographical risk regions. Eur Heart J. 2021;42:2455-67.
  19. Sundstrom J, Arima H, Jackson R, Turnbull F, Rahimi K, Chalmers J, et al. Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med 2015;162:184-91.
  20. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and metaregression analyses of randomized trials. J Hypertens 2014;32:2285-95.
  21. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs - overview and meta-analyses. J Hypertens 2015;33:195-211.
  22. Kist JM, Vos RC, Mairuhu ATA, Struijs JN, van Peet PG, Vos HMM, et al. SCORE2 cardiovascular risk prediction models in an ethnic and socioeconomic diverse population in the Netherlands: an external validation study. EClinicalMedicine. 2023;57:101862.
  23. Cooney MT, Vartiainen E, Laatikainen T, et al. Cardiovascular risk age: concepts and practicalities. Heart 2012;98:941-6.
  24. Cuende JI, Cuende N, Calaveras-Lagartos J. How to calculate vascular age with the SCORE project scales: a new method of cardiovascular risk evaluation. Eur Heart J 2010;31:2351-8.
  25. Jaspers NEM, Blaha MJ, Matsushita K, van der Schouw YT, Wareham NJ, Khaw KT, et al. Prediction of individualized lifetime benefit from cholesterol lowering, blood pressure lowering, antithrombotic therapy, and smoking cessation in apparently healthy people. Eur Heart J. 2020;41:1190-99.
  26. Hageman SHJ, McKay AJ, Ueda P, Gunn LH, Jernberg T, Hagström E, et al. Estimation of recurrent atherosclerotic cardiovascular event risk in patients with established cardiovascular disease: the updated SMART2 algorithm. Eur Heart J. 2022;43:1715-27.
  27. Kaasenbrood L, Bhatt DL, Dorresteijn JAN, Wilson PWF, D’Agostino RB Sr, Massaro JM, et al. Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model. J Am Heart Assoc. 2018;7:e009217.
  28. Østergaard HB, Hageman SHJ, Read SH, Taylor O, Pennells L, Kaptoge S, et al. Estimating individual lifetime risk of incident cardiovascular events in adults with Type 2 diabetes: an update and geographical calibration of the DIAbetes Lifetime perspective model (DIAL2). Eur J Prev Cardiol. 2023;30:61-69.
  29. Marx N, Federici M, Schütt K, Müller-Wieland D, Ajjan RA, Antunes MJ, et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes. Eur Heart J. 2023;44:4043-140.
  30. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007;115:450-8.
  31. Chapman MJ, Ginsberg HN, Amarenco P, et al. Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J 2011;32:1345-61.
  32. Fruchart JC, Sacks F, Hermans MP, et al. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008;102:1K-34K.
  33. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study. Lancet 2012;380:572-80.
  34. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010;31:2844-53.
  35. Mons U, Müezzinler A, Gellert C. Impact of smoking and smoking cessation on cardiovascular events and mortality among older adults: meta-analysis of individual participant data from prospective cohort studies of the CHANCES consortium. BMJ 2015;350:h1551.
  36. Iso H, Date C, Yamamoto A, et al. Smoking cessation and mortality from cardiovascular disease among Japanese men and women: the JACC Study. Am J Epidemiol 2005;161:170-9.
  37. Villareal DT, Chode S, Parimi N, et al. Weight loss, exercise, or both and physical function in obese older adults. N Engl J Med 2011;364:1218-29.
  38. Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Social Science & Medicine. 1999;49(5):651-661.
  39. Charles C, Gafni A, Whelan T. Decision-making in the physician-patient encounter: revisiting the shared treatment decision-making model. Cultural influences on the physician-patient encounter: the case of shared treatment decision-making. Patient Educ Couns 2006;63(3):262-7.
  40. Elwyn G, Frosch D, Thomson R, et al. Shared Decision Making: A Model for Clinical Practice J Gen Intern Med. 2012;27(10):1361-1367.
  41. Emanuel EJ, Emanuel LL. Proxy decision making for incompetent patients. An ethical and empirical analysis. JAMA 1992;267:2067-71.
  42. Stiggelbout AM, Van der Weijden T, De Wit M, et al. Shared decision making: really putting patients at the centre of healthcare. BMJ 2012:344:256.
  43. Legemaate J. Nieuwe verhoudingen in de spreekkamer: Juridische aspecten. Amsterdam: AMC, 2013.
  44. Wanneer samen beslissen niet meer van zelf spreekt. Den Haag: Centrum voor ethiek en gezondheid, 2014. Ga naar bron
  45. Bachmann JM, Willis BL, Ayers CR, et al. Association between family history and coronary heart disease death across long-term follow-up in men: the Cooper Center Longitudinal Study. Circulation 2012;125:3092-8.
  46. Tikkanen E, Havulinna AS, Palotie A, et al. Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease. Arterioscler Thromb Vasc Biol 2013;33:2261-6.
  47. Sivapalaratnam S, Boekholdt SM, Trip MD, et al. Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart 2010;96:1985-89.
  48. Veronesi G, Gianfagna F, Giampaoli S, et al. Improving long-term prediction of first cardiovascular event: the contribution of family history of coronary heart disease and social status. Prev Med 2014;64:75-80.
  49. Yeboah J, McClelland RL, Polonsky TS, et al. Comparison of novel risk markers for improvement in cardiovascular risk assessment in intermediate-risk individuals. JAMA 2012;308:788-95.
  50. Hughes MF, Saarela O, Stritzke J, et al. Genetic markers enhance coronary risk prediction in men: the MORGAM prospective cohorts. PLoS One 2012;7:e40922.
  51. Ganna A, Magnusson PK, Pedersen NL, et al. Multilocus genetic risk scores for coronary heart disease prediction. Arterioscl Thromb Vasc Biol 2013;33:2267-72.
  52. Guay SP, Brisson D, Lamarche B, et al. DNA methylation variations at CETP and LPL gene promoter loci: new molecular biomarkers associated with blood lipid profile variability. Atherosclerosis 2013;228:413-20.
  53. Wang X, Falkner B, Zhu H, et al. A genome-wide methylation study on essential hypertension in young African American males. PLoS One 2013;8:e53938.
  54. Baccarelli A, Wright R, Bollati V, et al. Ischemic heart disease and stroke in relation to blood DNA methylation. Epidemiology 2010;21:819-28.
  55. Albert MA, Glynn RJ, Buring J, et al. Impact of traditional and novel risk factors on the relationship between socioeconomic status and incident cardiovascular events. Circulation 2006;114:2619-26.
  56. Alter DA, Franklin B, Ko DT, et al. Socioeconomic status, functional recovery, and long-term mortality among patients surviving acute myocardial infarction. PLoS One 2014;8:e65130.
  57. Woodward M, Brindle P, Tunstall-Pedoe H. Adding social deprivation and family history to cardiovascular risk assessment: the ASSIGN score from the Scottish Heart Health Extended Cohort (SHHEC). Heart 2007;93:172-6.
  58. Barth J, Schneider S, Von Kanel R. Lack of social support in the etiology and the prognosis of coronary heart disease: a systematic review and meta-analysis. Psychosom Med 2010;72:229-38.
  59. Nawrot TS, Perez L, Kunzli N, et al. Public health importance of triggers of myocardial infarction: a comparative risk assessment. Lancet 2011;377:732-40.
  60. Mostofsky E, Penner EA, Mittleman MA. Outbursts of anger as a trigger of acute cardiovascular events: a systematic review and meta-analysis. Eur Heart J. 2014;35: 1404–1410.
  61. Kivimaki M, Nyberg ST, Batty GD, et al. Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data. Lancet 2012;380:1491-7.
  62. Eaker ED, Sullivan LM, Kelly-Hayes M, et al. Marital status, marital strain, and risk of coronary heart disease or total mortality: the Framingham Offspring Study. Psychosom Med 2007;69:509-13.
  63. Kivimaki M, Jokela M, Nyberg ST, et al. Long working hours and risk of coronary heart disease and stroke: a systematic review and meta-analysis of published and unpublished data for 603 838 individuals. Lancet 2015;386:1739-46.
  64. Spindler H, Pedersen SS. Posttraumatic stress disorder in the wake of heart disease: prevalence, risk factors, and future research directions. Psychosom Med 2005;67:715-23.
  65. Pogosova N, Saner H, Pedersen SS, et al. Psychosocial aspects in cardiac rehabilitation: from theory to practice. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation of the European Society of Cardiology. Eur J Prev Cardiol 2015;22:1290-306.
  66. Orth-Gomer K, Wamala SP, Horsten M, et al. Marital stress worsens prognosis in women with coronary heart disease: the Stockholm Female Coronary Risk Study. JAMA 2000;284:3008-14.
  67. Schnohr P, Marott JL, Kristensen TS, et al. Ranking of psychosocial and traditional risk factors by importance for coronary heart disease: the Copenhagen City Heart Study. Eur Heart J 2015;36:1385-93.
  68. Smoller JW, Pollack MH, Wassertheil-Smoller S, et al. Panic attacks and risk of incident cardiovascular events among postmenopausal women in the Women’s Health Initiative Observational Study. Arch Gen Psychiatry 2007;64:1153-60.
  69. Roest AM, Martens EJ, De Jonge P, et al. Anxiety and risk of incident coronary heart disease: a meta-analysis. J Am Coll Cardiol 2010a;56:38-46.
  70. Roest AM, Martens EJ, Denollet J, et al. Prognostic association of anxiety post myocardial infarction with mortality and new cardiac events: a meta-analysis. Psychosom Med 2010b;72:563-9.
  71. Fan Z, Wu Y, Shen J, et al. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. J Psychiatr Res. 2013;47: 1549–1556.
  72. Edmondson D, Kronish IM, Shaffer JA, et al. Posttraumatic stress disorder and risk for coronary heart disease: a meta-analytic review. Am Heart J 2013;166:806-14.
  73. Chida Y, Steptoe A. The association of anger and hostility with future coronary heart disease: a meta-analytic review of prospective evidence. J Am Coll Cardiol 2009;53:936-46.
  74. Grande G, Romppel M, Barth J. Association between type D personality and prognosis in patients with cardiovascular diseases: a systematic review and meta-analysis. Ann Behav Med 2012;43:299-310.
  75. Chandola T, Britton A, Brunner E, et al. Work stress and coronary heart disease: what are the mechanisms? Eur Heart J. 2008;29:640–648.
  76. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004;364:9.
  77. Stringhini S, Sabia S, Shipley M, et al. Association of socioeconomic position with health behaviors and mortality. JAMA 2010;303:1159-66.
  78. Lichtman JH, Froelicher ES, Blumenthal JA, et al. Depression as a risk factor for poor prognosis among patients with acute coronary syndrome: systematic review and recommendations: a scientific statement from the American Heart Association. Circulation 2014;129:1350-69.
  79. Albus C, Ladwig KH, Herrmann-Lingen C. (Psychocardiology: clinically relevant recommendations regarding selected cardiovascular diseases). Dtsch Med Wochenschr 2014;139:596-601.
  80. Al-Rawi S, Zolezzi M, Eltorki Y. Evaluation of cardiovascular risk in adult psychiatric outpatients in Qatar using two risk assessment tools. Qatar Med J. 2021;2021:27.
  81. Foguet-Boreu Q, Fernandez San Martin MI, Flores Mateo G, Zabaleta Del Olmo E, Ayerbe García-Morzon L, Perez-Piñar López M, et al. Cardiovascular risk assessment in patients with a severe mental illness: a systematic review and meta-analysis. BMC Psychiatry. 2016;16:141.
  82. Salvi V, Aguglia A, Barone-Adesi F, Bianchi D, Donfrancesco C, Dragogna F, et al. Cardiovascular risk in patients with severe mental illness in Italy. Eur Psychiatry. 2020;63:e96.
  83. Osborn DP, Hardoon S, Omar RZ, Holt RI, King M, Larsen J, et al. Cardiovascular risk prediction models for people with severe mental illness: results from the prediction and management of cardiovascular risk in people with severe mental illnesses (PRIMROSE) research program. JAMA Psychiatry. 2015;72:143-51.
  84. Aguglia A, Salvi V, Amerio A, Gari M, Dragogna F, Mencacci C, et al. Number of episodes and duration of illness associated with hypertension and 10-year cardiovascular risk in patients with bipolar disorder type I. Psychiatry Res. 2022;308:114344.
  85. Perry BI, Upthegrove R, Crawford O, Jang S, Lau E, McGill I, et al. Cardiometabolic risk prediction algorithms for young people with psychosis: a systematic review and exploratory analysis. Acta Psychiatr Scand. 2020;142:215-32.
  86. Cunningham R, Poppe K, Peterson D, Every-Palmer S, Soosay I, Jackson R. Prediction of cardiovascular disease risk among people with severe mental illness: A cohort study. PLoS One. 2019;14:e0221521.
  87. Lambert AM, Parretti HM, Pearce E, Price MJ, Riley M, Ryan R, et al. Temporal trends in associations between severe mental illness and risk of cardiovascular disease: A systematic review and meta-analysis. PLoS Med. 2022;19:e1003960.
  88. Rhee TG, Olfson M, Nierenberg AA, Wilkinson ST. 20-Year Trends in the Pharmacologic Treatment of Bipolar Disorder by Psychiatrists in Outpatient Care Settings. Am J Psychiatry. 2020;177:706-715.
  89. Pillinger T, McCutcheon RA, Vano L, Mizuno Y, Arumuham A, Hindley G, et al. Comparative effects of 18 antipsychotics on metabolic function in patients with schizophrenia, predictors of metabolic dysregulation, and association with psychopathology: a systematic review and network meta-analysis. Lancet Psychiatry. 2020;7:64-77.
  90. Jakobs K, Lautan L, Lucassen P, Janzing J, van Lieshout J, Biermans MCJ, et al. Cardiovascular risk management in patients with severe mental illness or taking antipsychotics: A qualitative study on barriers and facilitators among dutch general practitioners. Eur J Gen Pract. 2022;28:191-99.
  91. Kaptoge S, Di Angelantonio E, Pennells L, et al. C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012;367:1310-20.
  92. Gilstrap LG, Wang TJ. Biomarkers and cardiovascular risk assessment for primary prevention: an update. Clin Chem 2012;58:72-82.
  93. Tzoulaki I, Siontis KC, Evangelou E, et. Bias in associations of emerging biomarkers with cardiovascular disease. JAMA Intern Med 2013;173:664-71.
  94. Kooter AJ, Kostense PJ, Groenewold J, et al. Integrating information from novel risk factors with calculated risks: the critical impact of risk factor prevalence. Circulation 2011;124:741-5.
  95. Wurtz P, Havulinna AS, Soininen P, et al. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 2015;131:774–85.
  96. O’Leary DH, Polak JF, Kronmal RA, et al. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. N Engl J Med 1999;340:14-22.
  97. Chambless LE, Heiss G, Folsom AR, et al. Association of coronary heart disease incidence with carotid arterial wall thickness and major risk factors: the Atherosclerosis Risk in Communities (ARIC) Study, 1987 to 1993. Work stress and coronary heart disease: what are the mechanisms? Eur Heart J 2008;29:640-8.
  98. Den Ruijter HM, Peters SA, Anderson TJ, et al. Common carotid intima-media thickness measurements in cardiovascular risk prediction: a meta-analysis. JAMA 2012;308:796-803.
  99. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008;21:93-111; quiz 189-90.
  100. Taylor HA, Penman AD, Han H, et al. Left ventricular architecture and survival in African-Americans free of coronary heart disease (from the Atherosclerosis Risk in Communities (ARIC) study). Am J Cardiol 2007;99:1413-20.
  101. Muiesan ML, Salvetti M, Monteduro C, et al. Left ventricular concentric geometry during treatment adversely affects cardiovascular prognosis in hypertensive patients. Hypertension 2004;43:731-8.
  102. Evans JM, Wang J, Morris AD. Comparison of cardiovascular risk between patients with type 2 diabetes and those who had had a myocardial infarction: cross sectional and cohort studies. BMJ 2002;324:939-42.
  103. Wannamethee SG, Shaper AG, Whincup PH, et al. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. Arch Intern Med 2011;171:404-10.
  104. Constantino MI, Molyneaux L, Limacher-Gisler F, et al. Long-term complications and mortality in youngonset diabetes: type 2 diabetes is more hazardous and lethal than type 1 diabetes. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncology 2012;23(Suppl 7):vii155-66.
  105. Tonelli M, Muntner P, Lloyd A, et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: a population-level cohort study. Lancet 2012; 380:807-14.
  106. Angelantonio E, Kaptoge S, Wormser D, et al. Association of cardiometabolic multimorbidity with mortality. JAMA 2015;314:52-60.
  107. Lind M, Svensson AM, Kosiborod M, et al. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med 2014;371:1972-82.
  108. Woodward M, Hirakawa Y, Kengne AP, et al. ADVANCE Collaborative Group. Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. Diabetes Obes Metab. 2016;18(3):289-94.
  109. Zheng SL, Roddick AJ, Aghar-Jaffar R, et al. Association between use of sodium-glucose cotransporter 2 inhibitors, glucagon-like peptide 1 agonists, and dipeptidyl peptidase 4 inhibitors with all-cause mortality in patients with type 2 diabetes: a systematic review and meta-analysis. JAMA 2018 Apr 17;319:1580-91.
  110. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: effects on the cardiovascular system. Circulation 2007;116:85-97.
  111. Gansevoort RT, Correa-Rotter R, Hemmelgarn BR, et al. Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet 2013;382:339-52.
  112. Matsushita K, Van der Velde M, Astor BC, et al. Association of estimated glomerular filtration rate albuminuria with all-cause cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet 2010;375:2073-81.
  113. Mahmoodi BK, Matsushita K, Woodward M, et al. for the CKD Prognosis Consortium. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis. Lancet 2012;380:1649-61.
  114. Matsushita K, Coresh J, Sang Y, et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015;3:514-25.
  115. KDIGO, Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013;3:1-150.
  116. Shlipak MG, Matsushita K, Arnlov J, et al. Cystatin C versus creatinine in determining risk based on kidney function. N Engl J Med 2013;369:932-43.
  117. Chen J, Long JB, Hurria A, et al. Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer. J Am Coll Cardiol 2012;60:2504-12.
  118. Darby S, McGale P, Peto R, et al. Mortality from cardiovascular disease more than 10 years after radiotherapy for breast cancer: nationwide cohort study of 90 000 Swedish women. BMJ 2003;326:256-7.
  119. Smith GL, Smith BD, Buchholz TA, et al. Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 2008;26: 5119-25.
  120. Fajardo LF. Is the pathology of radiation injury different in small versus large blood vessels? Cardiovasc Radiat Med 1999;1:108-10.
  121. Van der Pal HJ, Van Dalen EC, Van Delden E, et al. High risk of symptomatic cardiac events in childhood cancer survivors. J Clin Oncol 2012;30:1429-37.
  122. Hooning MJ, Botma A, Aleman BM, et. Long-term risk of cardiovascular disease in 10-year survivors of breast cancer. J Natl Cancer Instit 2007;99:365-75.
  123. Yeh JM, Nohria A, Diller L. Routine echocardiography screening for asymptomatic left ventricular dysfunction in childhood cancer survivors: a model-based estimation of the clinical and economic effects. Ann Intern Med 2014;160:661-71.
  124. Jensen BV, Skovsgaard T, Nielsen SL. Functional monitoring of anthracycline cardiotoxicity: a prospective, blinded, long-term observational study of outcome in 120 patients. Ann Oncology 2002;13:699-709.
  125. Darby SC, Ewertz M, McGale P, et al. Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 2013;368:987-98.
  126. Mishra SI, Scherer RW, Snyder C, et al. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev. 2012;8:CD008465.
  127. McMurray JJ, Adamopoulos S, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Exercise interventions on health-related quality of life for people with cancer during active treatment. Cochrane Database Syst Rev 2012;8:CD008465.
  128. Plana JC, Galderisi M, Barac A, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging 2014;15:1063-93.
  129. Curigliano G, Cardinale D, Suter T, et al. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO Clinical Practice Guidelines. Ann Oncology. 2012;23(Suppl 7):vii155–vii166.
  130. Cardinale D, Colombo A, Lamantia G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 2010;55:213-20.
  131. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342:1077–1084.
  132. Agca R, Heslinga SC, Rollefstad S, et al. EULAR recommendations for cardiovascular disease risk management in patients with rheumatoid arthritis and other forms of inflammatory joint disorders: 2015/2016update. Ann Rheum Dis 2017;76:17-28.
  133. Hippisley-Cox J, Coupland C, Vinogradova Y, et al. Predicting cardiovascular risk in England and Wales: prospective derivation and validation of QRISK2. BMJ 2008;336:1475-82.
  134. Ogdie A, Yu Y, Haynes K, Love TJ, Maliha S, Jiang Y, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74:326-32.
  135. Polachek A, Touma Z, Anderson M, Eder L. Risk of Cardiovascular Morbidity in Patients With Psoriatic Arthritis: A Meta-Analysis of Observational Studies. Arthritis Care Res (Hoboken). 2017;69:67-74.
  136. Drosos GC, Vedder D, Houben E, Boekel L, Atzeni F, Badreh S, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis. 2022;81:768-79.
  137. Nasir K, Acquah I, Dey AK, Agrawal T, Hassan SZ, Glassner K, et al. Inflammatory bowel disease and atherosclerotic cardiovascular disease in U.S. adults-A population-level analysis in the national health interview survey. Am J Prev Cardiol. 2022;9:100316.
  138. Gonzaga C, Bertolami A, Bertolami M, et al. Obstructive sleep apnea, hypertension and cardiovascular diseases. J Hum Hypertens 2015;29:705-12.
  139. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991;14:540-5.
  140. Bellamy L, Casas JP, Hingorani AD, et al. Type 2 diabetes mellitus after gestational diabetes: a systematic review and meta-analysis. Lancet 2009;373:1773-9.
  141. Auvinen AM, Luiro K, Jokelainen J, Järvelä I, Knip M, Auvinen J, et al. Type 1 and type 2 diabetes after gestational diabetes: a 23 year cohort study. Diabetologia. 2020;63:2123-28.
  142. Kramer CK, Campbell S, Retnakaran R. Gestational diabetes and the risk of cardiovascular disease in women: a systematic review and meta-analysis. Diabetologia 2019;62:905-14.
  143. Nybo-Andersen AM, Wohlfahrt J, Christens P, Melbye M. Maternal age and fetal loss: population based register linkage study. BMJ 2000;320:1708-12.
  144. Oliver-Williams CT, Heydon EE, Smith GCS, Wood AM. Miscarriage and future maternal cardiovascular disease: a systematic review and meta-analysis. Heart 2013;99:1636-44.
  145. Heida KY, Bots ML, de Groot CJM, van Dunné FM, Hammoud NH. Cardiovascular risk management after reproductive and pregnancy-related disorders: A Dutch multidisciplinary evidence-based guideline. Eur j Prev Cardiol. 2016;23:1863-79.
  146. Tan YY, Gast GC. Gender differences in risk factors for coronary heart disease. Maturitas 2010;65:149-60.
  147. Wekker V, van Dammen L, Koning A, Heida KY, Painter R. Long-term cardiometabolic disease risk in women with PCOS: a systematic review and meta-analysis. Hum Reprod Update 2020;26:942-60.
  148. Gunning MN, Meun C, van Rijn BB, Daan NMP, Roeters van Lennep JE, Appelman Y, et al; CREW consortium. The cardiovascular risk profile of middle age women previously diagnosed with premature ovarian insufficiency: A case-control study. PLoS One. 2020;15:e0229576.
  149. Wormser, et al. The Emerging Risk Factors Collaboration. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011;377:1085-95.
  150. Van Dis, et al. Do obesity and parental history of myocardial infarction improve cardiovascular risk prediction? Eur J Prevent Cardio 2012;20:793-9.
  151. Peters SA, Den Ruijter HM, Bots ML, et al. Improvements in risk stratification for the occurrence of cardiovascular disease by imaging subclinical atherosclerosis: a systematic review. Heart 2012;98:177-84.
  152. Paixao ARM, Ayers CR, el Sabbagh A, et al. Coronary artery calcium improves risk classification in younger populations. J Am Coll Cardiol 2015;11:1285-93.
  153. Baber U, Mehran R, Sartori S, et al. Prevalence, impact, and predictive value of detecting subclinical coronary and carotid atherosclerosis in asymptomatic adults. J Am Coll Cardiol 2015;11:1065-74.
  154. Hoffmann U, Massaro JM, D'Agostino RB Sr, Kathiresan S, Fox CS, O'Donnell CJ. Cardiovascular Event Prediction and Risk Reclassification by Coronary, Aortic, and Valvular Calcification in the Framingham Heart Study. J Am Heart Assoc. 2016;5:e003144.
  155. Tinana A, Mintz GS, Weissman NJ. Volumetric intravascular ultrasound quantification of the amount of atherosclerosis and calcium in nonstenotic arterial segments. Am J Cardiol 2002;89:757-60.
  156. de Ronde MWJ, Khoshiwal A, Planken RN, Boekholdt SM, Biemond M, Budoff MJ, et al. A pooled-analysis of age and sex based coronary artery calcium scores percentiles. J Cardiovasc Comput Tomogr. 2020;14:414-20.
  157. Burke AP, Kolodgie FD, Farb A, Weber D, Virmani R. Morphological predictors of arterial remodeling in coronary atherosclerosis. Circulation. 2002;105:297-303.
  158. Grandhi GR, Mirbolouk M, Dardari ZA, Al-Mallah MH, Rumberger JA, Shaw LJ, et al. Interplay of Coronary Artery Calcium and Risk Factors for Predicting CVD/CHD Mortality: The CAC Consortium. JACC Cardiovasc Imaging. 2020;13:1175-86.
  159. Blaha MJ, Cainzos-Achirica M, Greenland P, McEvoy JW, Blankstein R, Budoff MJ, et al. Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA). Circulation. 2016;133:849-58.
  160. Hecht HS, Superko HR. Electron beam tomography and National Cholesterol Education Program guidelines in asymptomatic women. J Am Coll Cardiol. 2001;37:1506–11.
  161. Temtem M, Mendonça MI, Gomes Serrão M, Santos M, Sá D, Sousa F, et al. Predictive improvement of adding coronary calcium score and a genetic risk score to a traditional risk model for cardiovascular event prediction. Eur J Prev Cardiol. 2024;31:709-15.
  162. Haberl R, Becker A, Leber A, et al. Correlation of coronary calcification and angiographically documented stenoses in patients with suspected coronary artery disease: results of 1,764 patients. J Am Coll Cardiol 2001;37:451-7.
  163. Biavati F, Saba L, Boussoussou M, Kofoed KF, Benedek T, Donnelly P, et al; DISCHARGE Trial Group. Coronary Artery Calcium Score Predicts Major Adverse Cardiovascular Events in Stable Chest Pain. Radiology. 2024;310:e231557.
  164. Budoff MJ, Young R, Burke G, Jeffrey Carr J, Detrano RC, Folsom AR, et al. Ten-year association of coronary artery calcium with atherosclerotic cardiovascular disease (ASCVD) events: the multi-ethnic study of atherosclerosis (MESA). Eur Heart J. 2018;39:2401-8.
  165. Sarwar A, Shaw LJ, Shapiro MD, Blankstein R, Hoffmann U, Cury RC, et al. Diagnostic and prognostic value of absence of coronary artery calcification. JACC Cardiovasc Imaging. 2009;2:675-88.
  166. Golub IS, Termeie OG, Kristo S, Schroeder LP, Lakshmanan S, Shafter AM, et al. Major Global Coronary Artery Calcium Guidelines. JACC Cardiovasc Imaging. 2023;16:98-117.
  167. Venkataraman P, Huynh Q, Nicholls SJ, Stanton T, Watts GF, Marwick TH; CAUGHT-CAD investigators. Impact of a coronary artery calcium-guided statin treatment protocol on cardiovascular risk at 12 months: Results from a pragmatic, randomised controlled trial. Atherosclerosis. 2021;334:57-65.
  168. Chou R, Arora B, Dana T, et al. Screening asymptomatic adults for coronary heart disease with resting or exercise electrocardiography: systematic review to update the 2004 U.S. Preventive Services Task Force Recommendation (Internet). Rockville (MD): Agency for Healthcare Research and Quality (US), 2011 Sep.
  169. Shah AJ, Vaccarino V, Janssens AC, et al. An Electrocardiogram-based risk equation for incident cardiovascular disease from the National Health and Nutrition Examination Survey. JAMA Cardiol 2016 Oct 1;1:779-86.
  170. Auer R, Bauer DC, Marques-Vidal P, et al. Health ABC Study. Association of major and minor ECG abnormalities with coronary heart disease events. JAMA. 2012;307(14):1497-505.
  171. Graversen P, Abildstrøm SZ, Jespersen L, et al. Cardiovascular risk prediction: can systematic coronary risk evaluation (SCORE) be improved by adding simple risk markers? Results from the Copenhagen City Heart Study. Eur J Prev Cardiol 2016;23:1546-56.
  172. Desai CS, Ning H, Soliman EZ, et al. Electrocardiographic abnormalities and coronary artery calcium for coronary heart disease prediction and reclassification: the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2014;168:391-7.
  173. Cook NR, Paynter NP. Performance of reclassification statistics in comparing risk prediction models. Biom J 2011;53::237-58.
  174. Hiatt WR. Medical treatment of peripheral arterial disease and claudication. N Engl J Med 2001;24:344:1608-21.
  175. Ankle Brachial Index Collaboration, Fowkes FG, Murray GD, et al. Ankle brachial index combined with Framingham risk score to predict cardiovascular events and mortality: a meta-analysis. JAMA 2008;9:300:197-208.
  176. McDermott MM, Greenland P, Liu K, et al. The ankle brachial index is associated with leg function and physical activity: the Walking and Leg Circulation Study. Ann Intern Med 2002 Jun 18;136:873-83. Erratum in: Ann Intern Med 2003;139:306.
  177. Fowkes FG, Price JF, Stewart MC, et al. Aspirin for Asymptomatic Atherosclerosis Trialists. Aspirin for prevention of cardiovascular events in a general population screened for a low ankle brachial index: a randomized controlled trial. JAMA 2010;3:303:841-8.
  178. Lin JS, Olson CM, Johnson ES, et al. The ankle-brachial index for peripheral artery disease screening and cardiovascular disease prediction among asymptomatic adults: a systematic evidence review for the U.S. Preventive Services Task Force. Ann Intern Med 2013;3:159:333-41.
  179. Yeboah J, Young R, McClelland RL, et al. Utility of nontraditional risk markers in atherosclerotic cardiovascular disease risk assessment. J Am Coll Cardiol 2016;19:67:139-47.
  180. Velescu A, Clara A, Peñafiel J, et al. Adding low ankle brachial index to classical risk factors improves the prediction of major cardiovascular events. The REGICOR study. Atherosclerosis 2015;241:357-63.
  181. Ferket BS, Van Kempen BJ, Hunink MG, et al. Predictive value of updating Framingham risk scores with novel risk markers in the U.S. general population. PLoS One 2014;18:9:e88312.
  182. Fowkes FG, Murray GD, Butcher I, et al. Development and validation of an ankle brachial index risk model for the prediction of cardiovascular events. Eur J Prev Cardiol 2014;21:310-20.
  183. Gijsbers L, Dower JI, Mensink M, et al. Effects of sodium and potassium supplementation on blood pressure and arterial stiffness: a fully controlled dietary intervention study. J Hum Hypertens 2015;29;592-8.
  184. Drawz PE, Baraniuk S, Davis BR, et al. Cardiovascular risk assessment: addition of CKD and race to the Framingham equation. Am Heart J 2012;164:925-31.
  185. Patel JV, Vyas A, Cruickshank JK, et al. Impact of migration on coronary heart disease risk factors: comparison of Gujaratis in Britain and their contemporaries in villages of origin in India. Atherosclerosis 2006;185:297-306.
  186. Rafnsson SB, Bhopal RS, Agyemang C, et al. Sizable variations in circulatory disease mortality by region and country of birth in six European countries. Eur J Public Health 2013;23:594-605.
  187. Van Oeffelen AA, Vaartjes I, Stronks K, et al. Incidence of acute myocardial infarction in first and second generation minority groups: does the second generation converge towards the majority population? Int J Cardiol 2013;168:5422-9.
  188. Harding S, Rosato M, Teyhan A. Trends for coronary heart disease and stroke mortality among migrants in England and Wales, 1979-2003: slow declines notable for some groups. Heart 2008;94:463-70.
  189. Tillin T, Hughes AD, Whincup P, et al. Ethnicity and prediction of cardiovascular disease: performance of QRISK2 and Framingham scores in a U.K. tri-ethnic prospective cohort study (SABRE-Southall And Brent REvisited). Heart 2014;100:60-7.
  190. Glenday K, Kumar BN, Tverdal A, et al. Cardiovascular disease risk factors among five major ethnic groups in Oslo, Norway: the Oslo Immigrant Health Study. Eur J Cardiovasc Prev Rehabil 2006;13:348-55.
  191. Agyemang C, Ujcic-Voortman J, Uitenbroek D, et al. Prevalence and management of hypertension among Turkish, Moroccan and native Dutch ethnic groups in Amsterdam, the Netherlands: the Amsterdam Health Monitor Survey. J Hypertens 2006;24:2169-76.
  192. El Fakiri F, Bruijnzeels MA, Foets MM, et al. Different distribution of cardiovascular risk factors according to ethnicity: a study in a high-risk population. J Immigrant Minority Health 2008;10:559-65.
  193. Snijder MB, Agyemang C, Peters RJ, et al. Case finding and medical treatment of type 2 diabetes among different ethnic minority groups: the HELIUS Study. J Diabetes Res 2017:9896849.
  194. Bhopal RS, Bansal N, Fischbacher CM, et al. Ethnic variations in the incidence and mortality of stroke in the Scottish Health and Ethnicity Linkage Study of 4.65 million people. Eur J Prev Cardiol. 2012;19:1503–1508.
  195. Regidor E, de La Fuente L, Martinez D, et al. Heterogeneity in cause-specific mortality according to birthplace in immigrant men residing in Madrid, Spain. Ann Epidemiol. 2008;18:605–13.
  196. Bhopal RS, HumphryRW, Fischbacher CM. Changes in cardiovascular risk factors in relation to increasing ethnic inequalities in cardiovascular mortality: comparison of cross-sectional data in the Health Surveys for England 1999 and 2004. BMJ Open. 2013;3:e003485.
  197. Agyemang C, Kunst AE, Bhopal R, et al. Diabetes prevalence in populations of South Asian Indian and African origins: a comparison of England and the Netherlands. Epidemiology 2011;22:563-7.
  198. Agyemang C, Stronks K, Tromp N, et al. A cross-national comparative study of smoking prevalence and cessation between English and Dutch South Asian and African origin populations: the role of national context. Nicotine Tob Res 2010;12:557-66.
  199. Mathur R, Hull SA, Badrick E, et al. Cardiovascular multimorbidity: the effect of ethnicity on prevalence and risk factor management. Br J Gen Pract 2011;61: e262-70.
  200. Schofield P, Saka O, Ashworth M. Ethnic differences in blood pressure monitoring and control in south east London. Br J Gen Pract 2011;61:190-6.
  201. Agyemang C, Bindraban N, Mairuhu G, et al; SUNSET (Surinamese in The Netherlands: Study on Ethnicity and Health) Study Group. Prevalence, awareness, treatment, and control of hypertension among black Surinamese, South Asian Surinamese and white Dutch in Amsterdam, The Netherlands: the SUNSET study. J Hypertens 2005;23:1971-7.
  202. Agyemang C, Kieft S, Snijder MB, et al. Hypertension control in a large multi-ethnic cohort in Amsterdam, The Netherlands: the HELIUS study. Int J Cardiol 2015;183:180-9.
  203. Bindraban NR, Van Valkengoed IG, Mairuhu G, et al. Prevalence of diabetes mellitus and the performance of a risk score among Hindustani Surinamese, African Surinamese and ethnic Dutch: a cross-sectional population-based study. BMC Public Health 2008;8:271.
  204. Raza Q, Snijder MB, Seidell JC, et al. Comparison of cardiovascular risk factors and dietary intakes among Javanese Surinamese and South-Asian Surinamese in the Netherlands. The HELIUS study. BMC Res Notes. 2017;6:10(1):23.
  205. Li M, Hu X, Fan Y, et al. Hyperuricemia and the risk for coronary heart disease morbidity and mortality a systematic review and dose-response meta-analysis. Sci Rep 2016;6:19520.
  206. Kavousi M, Elias-Smale S, Rutten JH, et al. Evaluation of newer risk markers for coronary heart disease risk classification: a cohort study. Ann Intern Med 2012;156:438-44.
  207. Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012;64:2836-46.
  208. Semb AG, Kvien TK, DeMicco DA, et al. Effect of intensive lipid-lowering therapy on cardiovascular outcome in patients with and those without inflammatory joint disease. Arthritis Rheum 2012;64:2836-46.
  209. Li J, Siegrist J. Physical activity and risk of cardiovascular disease – a meta-analysis of prospective cohort studies. Int J Environ Res Public Health 2012;9:391-407.
  210. Gladman DD. Toward unraveling the mystery of psoriatic arthritis. Psoriasis and risk of nonfatal cardiovascular disease in U.S. women: a cohort study. Br J Dermatol 2012;166:811-8.
  211. Cebron Lipovec N, Beijers RJ, Van den Borst B, et al. The prevalence of metabolic syndrome in chronic obstructive pulmonary disease: a systematic review. COPD 2016;13:399-406.
  212. Müllerova H, Agusti A, Erqou S, et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest 2013;144:1163-78.
  213. Chen W, Thomas J, Sadatsafavi M, et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015;3:631-9.
  214. Janssens HJ, Arts PG, Schalk BW, et al. Gout and rheumatoid arthritis, both to keep in mind in cardiovascular risk management: a primary care retrospective cohort study. Joint Bone Spine 2017;84:59-64.
  215. Clarson LE, Hider SL, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Ann Rheum Dis. 2015a;74(4):642-7.
  216. Clarson LE, Hider SL, Belcher J, et al. Increased risk of vascular disease associated with gout: a retrospective, matched cohort study in the UK clinical practice research datalink. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol 2015b;22:335-43.
  217. Kok VC, Horng JT, Lin HL, et al. Gout and subsequent increased risk of cardiovascular mortality in non-diabetics aged 50 and above: a population-based cohort study in Taiwan. BMC Cardiovasc Disord 2012;12:108.
  218. Sattar N, McCarey DW, Capell H, et al. Explaining how ‘high-grade’ systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
  219. Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ 2017;357:j2099.
  220. Board JBS. Joint British Societies’ consensus recommendations for the prevention of cardiovascular disease (JBS3). Heart 2014;100(Suppl 2):ii1-67.
  221. Avina-Zubieta JA, Thomas J, Sadatsafavi M, et al. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012;71:1524-9.
  222. Lindhardsen J, Ahlehoff O, Gislason GH, et al. The risk of myocardial infarction in rheumatoid arthritis and diabetes mellitus: a Danish nationwide cohort study. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis 2015;74:326-32.
  223. Castañeda S, Martín-Martínez MA, González-Juanatey C, et al. Cardiovascular morbidity and associated risk factors in Spanish patients with chronic inflammatory rheumatic diseases attending rheumatology clinics: baseline data of the CARMA Project. Semin Arthritis Rheum 2015;44:618-26.
  224. Arts EE, Fransen J, Den Broeder AA, et al. The effect of disease duration and disease activity on the risk of cardiovascular disease in rheumatoid arthritis patients. Ann Rheum Dis 2015;74:998-1003.
  225. Demoruelle MK, Deane KD, Holers VM. When and where does inflammation begin in rheumatoid arthritis? Curr Opin Rheumatol 2014;26:64-71.
  226. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Epub 2016 May 3. Review. Erratum in: Lancet. 2016 Oct 22;388(10055):1984.
  227. Dregan A, Chowienczyk P, Molokhia M. Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders. Heart 2017. pii: heartjnl-2017-311214.
  228. Hung YM, Chang WP, Wei JC, et al. Midlife Ankylosing Spondylitis Increases the Risk of Cardiovascular Diseases in Males 5 Years Later: A National Population-Based Study. Medicine (Baltimore). 2016;95(18):e3596.
  229. Haroon NN, Paterson JM, Li P, et al. Patients with ankylosing spondylitis have increased cardiovascular and cerebrovascular mortality: a population-based study. Midlife ankylosing spondylitis increases the risk of cardiovascular diseases in males 5 years later: a national population-based study. Medicine (Baltimore) 2016;95:e3596.
  230. Szabo SM, Levy AR, Rao SR, et al. Increased risk of cardiovascular and cerebrovascular diseases in individuals with ankylosing spondylitis: a population-based study. Arthritis Rheum 2011;63:3294-304.
  231. Islam FM, Wu J, Jansson J, et al. Relative risk of cardiovascular disease among people living with hiv: a systematic review and meta-analysis. HIV Med 2012;13:453-68.
  232. Lundgren JD, Babiker AG, Gordin F, et al. INSIGHT START Study Group. Initiation of antiretroviral therapy in early asymptomatic hiv infection. N Engl J Med 2015 Aug 27;373:795-807.
  233. Singh S, Singh H, Loftus EV Jr, et al. Risk of cerebrovascular accidents and ischemic heart disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. Clin Gastroenterol Hepatol 2014;12:382-93.
  234. Xiao Z, Pei Z, Yuan M, et al. Risk of stroke in patients with inflammatory bowel disease: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis 2015;24:2774-80.
  235. Close H, Mason JM, Wilson DW, et al. Risk of ischaemic heart disease in patients with inflammatory bowel disease: cohort study using the general practice research database. PLoS One 2015;10:e0139745.
  236. Dregan A, Charlton J, Chowienczyk P, et al. Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke: a population-based cohort study. Circulation 2014;130:837-44.
  237. Jussila A, Virta LJ, Pukkala E, et al. Mortality and causes of death in patients with inflammatory bowel disease: a nationwide register study in Finland. J Crohns Colitis 2014;8:1088-96.
  238. Tsai MS, Lin CL, Chen HP, et al. Long-term risk of acute coronary syndrome in patients with inflammatory bowel disease: a 13-year nationwide cohort study in an Asian population. Inflamm Bowel Dis 2014;20:502-7.
  239. Artinian NT, Fletcher GF, Mozaffarian D, et al. Interventions to promote physical activity and dietary lifestyle changes for cardiovascular risk factor reduction in adults: a scientific statement from the American Heart Association. Circulation 2010;122:406-41.
  240. General Medical Council. Consent: patients and doctors making decisions together. Manchester, UK: General Medical Council, 2008.
  241. Rubak S, Sandbaek A, Lauritzen T, et al. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract 2005;55:305-12.
  242. Martin LR, DiMatteo MR, eds. The Oxford handbook of health communication, behaviour change, and treatment adherence. New York: Oxford University Press, 2014.
  243. U.S. Preventive Services Task Force. Guide to clinical preventive services. 2nd ed. Baltimore: Williams & Wilkins, 1996.
  244. Balady GJ, Williams MA, Ades PA, et al. American Heart Association Exercise CR. Core components of cardiac rehabilitation/secondary prevention programs: 2007 update: a scientific statement from the American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee, the Council on Clinical Cardiology; the Councils on Cardiovascular Nursing, Epidemiology and Prevention, and Nutrition, Physical Activity, and Metabolism; and the American Association of Cardiovascular and Pulmonary Rehabilitation. Circulation 2007;115:2675-82.
  245. Piepoli MF, Corra U, Benzer W, et al. Secondary prevention through cardiac rehabilitation: from knowledge to implementation. A position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur J Cardiovasc Prev Rehabil 2010;17:1-17.
  246. Auer R, Gaume J, Rodondi N, et al. Efficacy of in-hospital multidimensional interventions of secondary prevention after acute coronary syndrome: a systematic review and meta-analysis. Circulation 2008;117:3109-17.
  247. Janssen V, De Gucht V, Dusseldorp E, et al. Lifestyle modification programmes for patients with coronary heart disease: a systematic review and meta-analysis of randomized controlled trials. Eur J Prev Cardiol 2013;20:620-40.
  248. Hazelton G, Williams JW, Wakefield J, et al. Psychosocial benefits of cardiac rehabilitation among women compared with men. Zelfmanagement door mensen met chronische ziekten. Kennissynthese van onderzoek en implementatie in Nederland. Utrecht: NIVEL, 2015.
  249. Burell G, Granlund B. Women’s hearts need special treatment. Int J Behav Med 2002;9:228-42.
  250. Ladwig KH, Lederbogen F, Albus C, et al. Position paper on the importance of psychosocial factors in cardiology: update 2013. Ger Med Sci 2014;12:Doc09.
  251. Whalley B, Thompson DR, Taylor RS. Psychological interventions for coronary heart disease: Cochrane systematic review and meta-analysis. Int J Behav Med 2014;21:109-21.
  252. Huffman JC, Niazi SK, Rundell JR, et al. Essential articles on collaborative care models for the treatment of psychiatric disorders in medical settings: a publication by the academy of psychosomatic medicine research and evidence-based practice committee. Psychosomatics 2014b;55:109-22.
  253. Stewart JC, Perkins AJ, Callahan CM. Effect of collaborative care for depression on risk of cardiovascular events: data from the IMPACT randomized controlled trial. Psychosom Med. 2014;76:29–37.
  254. Glozier N, Christensen H, Naismith S, et al. Internet-delivered cognitive behavioural therapy for adults with mild to moderate depression and high cardiovascular disease risks: a randomized attention-controlled trial. PLoS One 2013;8:e59139.
  255. Rutledge T, Redwine LS, Linke SE, et al. A meta-analysis of mental health treatments and cardiac rehabilitation for improving clinical outcomes and depression among patients with coronary heart disease. Psychosom Med 2013;75:335-49.
  256. Blumenthal JA, Sherwood A, Babyak MA, et al. Exercise and pharmacological treatment of depressive symptoms in patients with coronary heart disease: results from the UPBEAT (Understanding the Prognostic Benefits of Exercise and Antidepressant Therapy) study. J Am Coll Cardiol 2012;60:1053-63.
  257. Lie I, Arnesen H, Sandvik L, et al. Effects of a home-based intervention program on anxiety and depression 6 months after coronary artery bypass grafting: a randomized controlled trial. J Psychosom Res 2007;62:411-8.
  258. Page T, Lockwood C, Conroy-Hiller T. Effectiveness of nurse-led cardiac clinics in adult patients with a diagnosis of coronary heart disease. Int J Evid Based Healthcare 2005;3:2-26.
  259. Bishop GD, Kaur D, Tan VL, et al. Effects of a psychosocial skills training workshop on psychophysiological and psychosocial risk in patients undergoing coronary artery bypass grafting. Am Heart J 2005;150:602-9.
  260. Theorell T, Emdad R, Arnetz B, et al. Employee effects of an educational program for managers at an insurance company. Psychosom Med. 2001;63:724–733.
  261. Gezondheidsraad (2017a). Physical activity and risk of chronic diseases. Background document to the Dutch physical activity guidelines 2017. Den Haag: Gezondheidsraad, 2017; publicatienr. 2017/08B.
  262. Sattelmair J, Pertman J, Ding EL, et al. Dose response between physical activity and risk of coronary heart disease: a meta-analysis. Circulation 2011;124:789-95.
  263. Pandey A, Garg S, Khunger M, et al. Dose-response relationship between physical activity and risk of heart failure: a meta-analysis. Circulation 2015;132:1786-94.
  264. Cornelissen VA, Smart NA. Exercise training for blood pressure: a systematic review and meta-analysis. J Am Heart Assoc 2013;2:e004473.
  265. Murtagh EM, Nichols L, Mohammed MA, et al. The effect of walking on risk factors for cardiovascular disease: an updated systematic review and meta-analysis of randomised control trials. Prev Med 2015;72:34-43.
  266. Inder JD, Carlson DJ, Dieberg G, et al. Isometric exercise training for blood pressure management: a systematic review and meta-analysis to optimize benefit. Hypertens Res 2016;39:88-94.
  267. Gao HL, Gao HX, Sun FM, et al. Effects of walking on body composition in perimenopausal and postmenopausal women: a systematic review and meta-analysis. Menopause 2016;23:928-34.
  268. Hespanhol Junior LC, Pillay JD, Van Mechelen W, et al. Metaanalyses of the effects of habitual running on indices of health in physically inactive adults. Sports Med 2015;45:1455-68.
  269. Kuhle CL, Steffen MW, Anderson PJ, et al. Effect of exercise on anthropometric measures and serum lipids in older individuals: a systematic review and meta-analysis. BMJ open 2014;4:e005283.
  270. Mann S, Beedie C, Balducci S, et al. Changes in insulin sensitivity in response to different modalities of exercise: a review of the evidence. Diabetes Metab Res Rev 2014;30:257-68.
  271. Lin X, Zhang X, Guo J, et al. Effects of exercise training on cardiorespiratory fitness and biomarkers of cardiometabolic health: a systematic review and meta-analysis of randomized controlled trials. J Am Heart Assoc 2015;4. pii: e002014.
  272. Weber Buchholz S, Wilbur J, Halloway S, et al. Physical activity intervention studies and their relationship to body composition in healthy women. Kasper CE, Smith BA (editors). Annual review of nursing research. Excercise in health and disease. New York: Springer Publishing Company, 2013:71-142.
  273. Thorogood A, Mottillo S, Shimony A, et al. Isolated aerobic exercise and weight loss: a systematic review and meta-analysis of randomized controlled trials. Am J Med 2011;124:747-55.
  274. US Department of Health and Human Services. Phyiscal activity guidelines advisory committee report. Washington: US Department of Health and Human Services, 2008.
  275. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care 1997;20:537-44.
  276. Cloostermans L, Wendel-Vos W, Doornbos G, et al. Independent and combined effects of physical activity and body mass index on the development of type 2 diabetes – a metaanalysis of 9 prospective cohort studies. Int J Behav Nutr Phys Act 2015;12:147.
  277. Aune D, Norat T, Leitzmann M, et al. Physical activity and the risk of type 2 diabetes: a systematic review and dose-response meta-analysis. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and metaanalysis. Ann Intern Med 2015;162:123-32.
  278. Gezondheidsraad. (2017b) Sedentary behaviour and the risk of chronic diseases. Background document to the Dutch physical activity guidelines 2017. Den Haag: Gezondheidsraad, 2017; publicatienr. 2017/08C.
  279. Ekelund U, Steene-Johannessen J, Brown WJ, et al. Does physical activity attenuate, or even eliminate, the detrimental association of sitting time with mortality? A harmonized meta-analysis of data from more than 1 million men and women. Lancet 2016;388:1302-10.
  280. Wilmot EG, Edwardson CL, Achana FA, et al. Sedentary time in adults and the association with diabetes, cardiovascular disease and death: systematic review and metaanalysis. Diabetologia 2012;55:2895-905.
  281. Biswas A, Oh PI, Faulkner GE, et al. Sedentary time and its association with risk for disease incidence, mortality, and hospitalization in adults: a systematic review and metaanalysis. Annals of internal medicine. 2015;162(2):123-32.
  282. Zhou Y, Zhao H, Peng C. Association of sedentary behavior with the risk of breast cancer in women: update meta-analysis of observational studies. Ann Epidemiol 2015;25:687-97.
  283. Cong YJ, Gan Y, Sun HL, et al. Association of sedentary behaviour with colon and rectal cancer: a meta-analysis of observational studies. Br J Cancer 2014;110:817-26.
  284. Zhai L, Zhang Y, Zhang D. Sedentary behaviour and the risk of depression: a meta-analysis. Br J Sports Med 2015;49:705-9.
  285. Doll R, Peto R, Boreham J, et al. Mortality in relation to smoking: 50 years’ observations on male British doctors. BMJ 2004;328:1519.
  286. Kiiskinen U, Vartiainen E, Puska P, et al. Long-term cost and life-expectancy consequences of hypertension. J Hypertens 1998;16:1103-12.
  287. Kotseva K, Wood D, De Bacquer D, et al. EUROASPIRE IV: a European Society of Cardiology survey on the lifestyle, risk factor and therapeutic management of coronary patients from 24 European countries. Eur J Prev Cardiol 2016;23:636-48.
  288. Hartstichting. Infosheet Roken Ga naar bron
  289. Prescott E, Scharling H, Osler M, et al. Importance of light smoking and inhalation habits on risk of myocardial infarction and all cause mortality. A 22 year follow up of 12 149 men and women in the Copenhagen City Heart Study. J Epidemiol Community Health 2002;56:702-6.
  290. Critchley J, Capewell S. Smoking cessation for the secondary prevention of coronary heart disease. Cochrane Database Syst Rev 2004;1:CD003041.
  291. Woolf KJ, Zabad MN, Post JM, et al. Effect of nicotine replacement therapy on cardiovascular outcomes after acute coronary syndromes. Am J Cardiol 2012;110:968-70.
  292. Centers for Disease Control and Prevention. How tobacco smoke causes disease: the biology and behavioural basis for smoking-attributable disease 2010. A Report of the Surgeon General. Ga naar bron
  293. He J, Vupputuri S, Allen K, et al. Passive smoking and the risk of coronary heart disease – a meta-analysis of epidemiologic studies. N Engl J Med 1999;340:920-6.
  294. Law MR, Morris JK, Wald NJ. Environmental tobacco smoke exposure and ischaemic heart disease: an evaluation of the evidence. BMJ 1997;315:973-80.
  295. Joseph AM, Norman SM, Ferry LH, et al. The safety of transdermal nicotine as an aid to smoking cessation in patients with cardiac disease. N Engl J Med 1996;335:1792-8.
  296. Chow CK, Jolly S, Rao-Melacini P, et al. Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. Circulation 2010;121:750-8.
  297. Stead LF, Bergson G, Lancaster T. Physician advice for smoking cessation. Cochrane Database Syst Rev 2008;2:CD000165.
  298. Heatherton TF, Kozlowski LT, Frecker RC, et al. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. Br J Addict 1991;86:1119-27.
  299. Trimbos. Richtlijn behandeling van tabaksverslaving en stoppen met roken ondersteuning (herziening 2016).
  300. Gezondheidsraad. Voedingsvezel – Achtergronddocument bij Richtlijnen goede voeding 2015. Den Haag: Gezondheidsraad, 2015; publicatienr. A15/30.
  301. Gezondheidsraad. Voedingsnormen energie, eiwitten, vetten en verteerbare koolhydraten, 2001.
  302. Brink L, Postma-Smeets A, Stafleu A, Wolvers D. Richtlijnen Schijf van Vijf. Den Haag: Voedingscentrum, 2015
  303. Holmes MV, Dale CE, Zuccolo L, et al.; InterAct Consortium. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individualparticipant data. BMJ. 2014 Jul 10;349:g4164.
  304. Sacks FM, Lichtenstein AH, Wu JHY, et al. Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association. Circulation 2017;136:18.
  305. Mensink RP. Effects of saturated fatty acids on serum lipids and lipoproteins: a systematic review and regression analysis. Geneva: World Health Organization, 2016.
  306. Olde Engberink RHG, Van den Hoek TC, Van Noordenne ND, et al. Use of a single baseline versus multi-year 24-hour urine collections for estimation of long-term sodium intake and associated cardiovascular and renal risk. Circulation 2017 Sep 5;136:917-26.
  307. European Heart Network. Transforming European food and drink policies for cardiovascular health. Brussels, Belgium: European Heart Network, 2017.
  308. Astrup A, Dyerberg J, Elwood P, et al. The role of reducing intakes of saturated fat in the prevention of cardiovascular disease: where does the evidence stand in 2010? Am J Clin Nutr 2011;93:684-8.
  309. EFSA. Scientific Opinion on Dietary Reference Values for fats, including saturated fatty acids, polyunsaturated fatty acids, monounsaturated fatty acids, trans fatty acids, and cholesterol. EFSA Journal 2010;8:1461.
  310. Li Y et al. Saturated fats compared with unsaturated fats and sources of carbohydrates in relation to risk of coronary heart disease. A prospective cohort study. JACC 2015;66:1538-48.
  311. Wang X, Ouyang Y, Liu J, et al. Fruit and vegetable consumption and mortality from all causes, cardiovascular disease, and cancer: systematic review and dose-response meta-analysis of prospective cohort studies. Association of specific dietary fats with total and cause-specific mortality. JAMA Intern Med 2016;176:1134-45.
  312. Wen YT, Dai JH, Gao Q. Effects of omega-3 fatty acid on major cardiovascular events and mortality in patients with coronary heart disease: a meta-analysis of randomized controlled trials. Nutrition, metabolism, and cardiovascular diseases. Nutr Metab Cardiovasc Dis 2014;24:470-5.
  313. Rizos EC, Ntzani EE, Bika E, et al. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012;308:1024-33.
  314. Kromhout D, Giltay EJ, Geleijnse JM; Alpha Omega Trial Group. n-3 fatty acids and cardiovascular events after myocardial infarction. N Engl J Med 2010;363:2015-26.
  315. Sijtsma FPC, Soedamah-Muthu SS, De Goed J et al. Healthy eating and lower mortality risk in a large cohort of cardiac patients who received state-of-the art drug treatment. Am J Clin Nutr 2015 Dec;102:1527-33.
  316. Mozaffarian D, Katan MB, Ascherio A, et al. Trans fatty acids and cardiovascular disease. N Engl J Med 2006;354:1601-13.
  317. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. Lancet 2006;367:320-6.
  318. Sacks FM, Svetkey LP, Vollmer WM, et al. Effects on blood pressure of reduced dietary sodium the Dietary Approaches to Stop Hypertension (DASH) diet. DASH-Sodium Collaborative Research Group. N Engl J Med 2001;344:3-10.
  319. O’Donnell MJ, Yusuf S, Mente A et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 2011;306:2229-38.
  320. Aburto NJ, Hanson S, Gutierrez H, et al. Effect of increased potassium intake on cardiovascular risk factors and disease: systematic review and meta-analyses. BMJ 2013;346:f1378.
  321. Chowdhury R, Stevens S, Gorman D, et al. Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ 2012;345:e6698.
  322. Threapleton DE, Greenwood DC, Evans CE, et al. Dietary fibre intake and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 2013;347:f6879.
  323. Zhang Z, Xu G, Liu D, et al. Dietary fiber consumption and risk of stroke. Eur J Epidemiol. 2013;28:119–130.
  324. Yao B, Fang H, XuW, et al. Dietary fiber intake and risk of type 2 diabetes: a dose-response analysis of prospective studies. Eur J Epidemiol 2014;29:79-88.
  325. Gezondheidsraad. Richtlijn voor de vezelconsumptie, Gezondheidsraad, 2006
  326. Dauchet L, Amouyel P, Hercberg S, et al. Fruit and vegetable consumption and risk of coronary heart disease: a meta-analysis of cohort studies. J Nutr 2006;136:2588-93.
  327. Luo C, Zhang Y, Ding Y, et al. Nut consumption and risk of type 2 diabetes, cardiovascular disease, and all-cause mortality: a systematic review and meta-analysis. Am J Clin Nutr 2014;100:256-69.
  328. Zheng J, Huang T, Yu Y, et al. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr. 2012;15:725–737.
  329. Chowdhury R, Kunutsor S, Vitezova A, et al. Vitamin D and risk of cause specific death: systematic review and meta-analysis of observational cohort and randomised intervention studies. BMJ 2014;348:g1903.
  330. Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671.
  331. De Ruyter JC, Olthof MR, Seidell JC, et al. A trial of sugar-free or sugar-sweetened beverages and body weight in children. N Engl J Med 2012;367:1397-406.
  332. World Health Organization. Guideline: Sugars intake for adults and children. Geneva: World Health Organization, 2015.
  333. Rogers PJ, Hogenkamp PS, de Graaf C et al. Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. Int J Obes. 2016;40:381-394.
  334. Gezondheidsraad. Richtlijn Gezonde Voeding, 2015.
  335. Ras RT, Geleijnse JM, Trautwein EA. LDL-cholesterol-lowering effect of plant sterols and stanols across different dose ranges: a meta-analysis of randomised controlled studies. Br J Nutr 2014;112:214-9.
  336. Li Y, Jiang L, Jia Z, et al. A meta-analysis of red yeast rice: an effective and relatively safe alternative approach for dyslipidemia. PLoS One. 2014;9(6):e98611.
  337. EFSA, 2018 website. Geraadpleegd op 14-06-2018. Ga naar bron
  338. Lareb. Red yeast rice – an overview of the reported ADRs. Gepubliceerd op 11 juli 2017. Ga naar bron
  339. Brouwers JR, Roeters van Lennep JE, Maas AH. (‘Rode gist rijst’ als cholesterolverlager? Een waarschuwing is op zijn plaats. Ned Tijdschr Geneeskd 2016;160:D99.
  340. Catapano AL, Graham I, De Backer G, et al. (2016 ESC/EAS Guidelines for the Management of Dyslipidaemias). Kardiol Pol.2016;74:1234-1318.
  341. Maki KC, Palacios OM, Bell M, Toth PP. Use of supplemental long-chain omega-3 fatty acids and risk for cardiac death: an updated meta-analysis and review of research gaps. J Clin Lipidol 2017 Sep - Oct;11:1152-60.
  342. Aung et al. Associations of omega-3 fatty acid supplement use with cardiovascular disease risks. JAMA Cardiol, 2018: doi:10.1001/jamacardio.2017.5205.
  343. Sofi F, Abbate R, Gensini GF, et al. Accruing evidence on benefits of adherence to the Mediterranean diet on health: an updated systematic review and meta-analysis. Am J Clin Nutr 2010;92:1189-96.
  344. Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368:1279-1290.
  345. Van Rossum CTM, Buurma-Rethans EJM, Fransen HP, et al. Zoutconsumptie van kinderen en volwassenen in Nederland. Resultaten uit de Voedselconsumptiepeiling 2007 tot 2010. Bilthoven: RIVM-rapport 350050007/2012.
  346. Van Rossum CTM, Buurma EJM, Vennemann, FBC et al. Voedselcomsuptie in 2012 tot 2014 vergeleken met de Richtlijnen geode voeding 2015. Bilthoven: RIVM Briefrapport 2017-0095.
  347. Hendriksen M. et al. Zout-, jodium- en kaliuminname 2015. Voedingsstatusonderzoek bij volwassenen uit Doetinchem. RIVM Briefrapport 2016-0081.
  348. Hartstichting, 2016 Ga naar bron
  349. Hartstichting, 2015 Ga naar bron
  350. Poirier P, Alpert MA, Fleisher LA, et al. Cardiovascular evaluation and management of severely obese patients undergoing surgery: a science advisory from the American Heart Association. Circulation 2009;120:86-95.
  351. Emerging Risk Factors Collaboration, Wormser D, Kaptoge Set al. Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studies. Lancet 2011;377:1085-95.
  352. Kramer CK, Zinman B, Retnakaran R. Are metabolically healthy overweight and obesity benign conditions? A systematic review and meta-analysis. Ann Intern Med 2013;159:758-69.
  353. Van der A DL, Nooyens AC, Van Duijnhoven FJ, et al. All-cause mortality risk of metabolically healthy abdominal obese individuals: the EPICMORGEN study. Obesity 2014;22:557-64.
  354. Bell JA, Hamer M, Sabia S, et al. The natural course of healthy obesity over 20 years. J Am Coll Cardiol 2015;65:101-2.
  355. Iliodromiti S, Celis-Morales CA, Lyall DM, et al. The impact of confounding on the associations of different adiposity measures with the incidence of cardiovascular disease: a cohort study of 296 535 adults of white European descent. Eur Heart J 2018 May 1;39:1514-20.
  356. Oreopoulos A, Padwal R, Norris CM, et al. Effect of obesity on short- and long-term mortality postcoronary revascularization: a meta-analysis. Obesity 2008;16:442-50.
  357. Romero-Corral A, Montori VM, Somers VK, et al. Association of bodyweight with total mortality and with cardiovascular events in coronary artery disease: a systematic review of cohort studies. Lancet 2006;368:666-78.
  358. Barry VW, Baruth M, Beets MW, et al. Fitness versus fatness on all-cause mortality: a meta-analysis. Prog Cardiovasc Dis 2014;56:382-90.
  359. Lassale C, Tzoulaki I, Moons KGM, et al. Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis. Eur Heart J 2017;14.
  360. Ekelund U, Ward HA, Norat T, et al. Physical activity and all-cause mortality across levels of overall and abdominal adiposity in European men and women: the European Prospective Investigation into Cancer and Nutrition Study (EPIC). Am J Clin Nutr 2015;101:613-21.
  361. Berrington de Gonzalez A, Hartge P, Cerhan JR, et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010;363:2211-9.
  362. Kwok CS, Pradhan A, Khan MA, et al. Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol 2014;173:20-8.
  363. Richtlijn Diagnostiek en behandeling van obesitas bij volwassenen en kinderen (CBO, 2008). Ga naar bron
  364. Nordestgaard BG, Langsted A, Mora S, et al; European Atherosclerosis Society (EAS) and the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) joint consensus initiative. Fasting is not routinely required for determination of a lipid profile: clinical and laboratory implications including flagging at desirable concentration cut-points-a joint consensus statement from the European Atherosclerosis Society and European Federation of Clinical Chemistry and Laboratory Medicine. Eur Heart J 2016;37:1944-58.
  365. Borén J, Chapman MJ, Krauss RM, Packard CJ, Bentzon JF, Binder CJ, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: pathophysiological, genetic, and therapeutic insights: a consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2020;41:2313-30.
  366. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
  367. Chan DK, O’Rourke F, Shen Q, et al. Meta-analysis of the cardiovascular benefits of intensive lipid lowering with statins. Acta Neurol Scand 2011;124:188-95.
  368. Nußbaumer B, Glechner A, Kaminski-Hartenthaler A, et al. Ezetimibe-Statin Combination Therapy. Dtsch Arztebl Int 2016;113:445-53.
  369. Schmidt AF, Pearce LS, Wilkins JT, et al. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease. Cochrane Database Syst Rev 2017;4:CD011748.
  370. Amarenco P, Kim JS, Labreuche J, Charles H, Giroud M, Lee BC, et al; Treat Stroke to Target Investigators. Benefit of Targeting a LDL (Low-Density Lipoprotein) Cholesterol <70 mg/dL During 5 Years After Ischemic Stroke. Stroke. 2020a;51:1231-39.
  371. Schwartz GG, Steg PG, Szarek M, Bhatt DL, Bittner VA, Diaz R, et al.; ODYSSEY OUTCOMES Committees and Investigators. Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. N Engl J Med. 2018;379:2097-2107.
  372. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Béjot Y, et al; Treat Stroke to Target Investigators. A Comparison of Two LDL Cholesterol Targets after Ischemic Stroke. N Engl J Med. 2020b;382:9.
  373. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet 2008;371:117-25.
  374. Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
  375. Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459-72.
  376. Silverman MG, Ference BA, Im K, Wiviott SD, Giugliano RP, Grundy SM, et al. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. JAMA. 2016;316:1289-97.
  377. Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012;380:581-90.
  378. Wei Y, Jin Z, Shen G, et al. Effects of intensive antihypertensive treatment on Chinese hypertensive patients older than 70 years. J Clin Hypertens (Greenwich) 2013;15:420-7.
  379. Soran H, Adam S, Durrington PN. Are recent statin recommendations to employ fixed doses and abandon targets effective for treatment of hypercholesterolaemia? Investigation based on number needed to treat. Eur J Prev Cardiol. 2017;24:76-83.
  380. Hong SJ, Lee YJ, Lee SJ, Hong BK, Kang WC, Lee JY, et al; LODESTAR Investigators. Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial. JAMA. 2023;329:1078-87.
  381. Furtado RH, Giugliano RP. What Lessons Have We Learned and What Remains to be Clarified for PCSK9 Inhibitors? A Review of FOURIER and ODYSSEY Outcomes Trials. Cardiol Ther. 2020;9:59-73.
  382. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis. JAMA 2012;307:1302-9.
  383. Arsenault BJ, Rana JS, Stroes ES, et al. Beyond low-density lipoprotein cholesterol: respective contributions of non-high-density lipoprotein cholesterol levels, triglycerides, and the total cholesterol/high-density lipoprotein cholesterol ratio to coronary heart disease risk in apparently healthy men and women. J Am Coll Cardiol 2009;55:35-41.
  384. Van den Berg MJ, Van der Graaf Y, De Borst GJ, et al. Low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, triglycerides, and apolipoprotein B and cardiovascular risk in patients with manifest arterial disease. Am J Cardiol 2016;118:804-10.
  385. Arimura T, Miura S, Ike A, et al. Comparison of the efficacy and safety of statin and statin/ezetimibe therapy after coronary stent implantation in patients with stable angina. J Cardiol. 2012 Aug;60(2):111-8.
  386. Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004 Jun 15;93(12):1481-6.
  387. Cannon CP, Blazing MA, Giugliano RP, et al; IMPROVE-IT Investigators. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97.
  388. Masuda J, Tanigawa T, Yamada T, et al. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J. 2015 May 13;56(3):278-85.
  389. West AM, Anderson JD, Meyer CH, et al. The effect of ezetimibe on peripheral arterial atherosclerosis depends upon statin use at baseline. Atherosclerosis 2011 Sep;218:156-62.
  390. Dagli N, Yavuzkir M, Karaca I. The effects of high dose pravastatin and low dose pravastatin and ezetimibe combination therapy on lipid, glucose metabolism and inflammation. Inflammation 2007 Dec;30:230-5.
  391. Gaudiani LM, Lewin A, Meneghini L, et al. Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients. Diabetes Obes Metab. 2005 Jan;7(1):88-97.
  392. Meaney A, Ceballos G, Asbun J, et al. The VYtorin on Carotid intima-media thickness and overall arterial rigidity (VYCTOR) study. J Clin Pharmacol. 2009 Jul;49(7):838-47.
  393. Nakamura T, Hirano M, Kitta Y, et al. A comparison of the efficacy of combined ezetimibe and statin therapy with doubling of statin dose in patients with remnant lipoproteinemia on previous statin therapy. J Cardiol. 2012 Jul;60(1):12-7.
  394. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebocontrolled trial. Lancet 2004;364:685-96.
  395. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomized placebo-controlled trial. Lancet 2003;361:2005-16.
  396. Stroes ES, Thompson PD, Corsini A, et al. Statin-associated muscle symptoms: impact on statin therapy – European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management. Eur Heart J 2015;36:1012-22.
  397. Reiner Z, Galic M, Hanzevacki M, et al. (Concomitant use of statins and cytochrome P 450 inhibitors in Croatia). Lijecnicki vjesnik 2005;127:65-8.
  398. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One. 2012;7:e29849.
  399. Waters DD, Ho JE, DeMicco DA, et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. J Am Coll Cardiol 2011;57:1535-45.
  400. Culver AL, Ockene IS, Balasubramanian R, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women’s Health Initiative. Arch Intern Med 2012;172:144-52.
  401. Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375:735-42.
  402. Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet 2015;385:351-61.
  403. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22.
  404. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
  405. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomized controlled trial. Lancet 2007;370:1687-97.
  406. Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010;362:1563-74. Erratum in: N Engl J Med 2010 May 6;362:1748.
  407. Koren MJ, Sabatine MS, Giugliano RP, et al. Long-term low-density lipoprotein cholesterol-lowering efficacy, persistence, and safety of evolocumab in treatment of hypercholesterolemia: results up to 4 years from the open-label OSLER-1 extension study. Effect of combination therapy of ezetimibe and rosuvastatin on regression of coronary atherosclerosis in patients with coronary artery disease. Int Heart J 2015 May 13;56:278-85.
  408. Collier DJ, Poulter NR, Dahlöf B, et al. Impact of atorvastatin among older and younger patients in the Anglo-Scandinavian Cardiac Outcomes Trial Lipid-Lowering Arm. J Hypertens 2011;29:592-9.
  409. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998-3007.
  410. Shepherd J, Blauw GJ, Murphy MB, et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002;360:1623-30.
  411. Teng M, Lin L, Zhao YJ, et al. Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis. Drugs Aging 2015;32:649-61.
  412. Trompet S, Van Vliet P, De Craen AJ, et al. Pravastatin and cognitive function in the elderly. Results of the PROSPER study. J Neurol 2010;257:85-90.
  413. Stam-Slob MC, Visseren FL, Wouter Jukema J, et al. Personalized absolute benefit of statin treatment for primary or secondary prevention of vascular disease in individual elderly patients. Clin Res Cardiol 2016. (Epub ahead of print).
  414. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–2397.
  415. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2224-60.
  416. Kannel WB, Gordon T, Schwartz MJ. Systolic versus diastolic blood pressure and risk of coronary heart disease. The Framingham study. Am J Cardiol. 1971;27:335-46.
  417. Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic, and cardiovascular risks. US population data. Arch Intern Med 1993;153:598-615.
  418. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med 1992;152:1490-1500.
  419. Benetos A, Thomas F, Bean K, et al. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men. Arch Intern Med 2002;162:577-81.
  420. Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Levy D. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 1999;34:381-5.
  421. Koek HL, Grobbee DE, Bots ML. Trends in cardiovasculaire ziekte en sterfte in Nederland, 1980 tot 2000. Ned Tijdschr Geneeskd 2004;148:27-32.
  422. Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTT)a. Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. Lancet. 2021a;397:1625-36.
  423. Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTT)b. Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. Lancet. 2021b;398:1053-64.
  424. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
  425. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al.; ESC Scientific Document Group. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J. 2018;39:3021-3104.
  426. Fox CS, Larson MG, Leip EP, Culleton B, Wilson PW, Levy D. Predictors of new-onset kidney disease in a community-based population. JAMA. 2004;291:844-50.
  427. Obermayr RP, Temml C, Knechtelsdorfer M, Gutjahr G, Kletzmayr J, Heiss S, et al. Predictors of new-onset decline in kidney function in a general middle-european population. Nephrol Dial Transplant. 2008;23:1265-73.
  428. Levy D, Larson MG, Vasan RS, Kannel WB, Ho KK. The progression from hypertension to congestive heart failure. JAMA. 1996;275:1557-62.
  429. Aune D, Mahamat-Saleh Y, Kobeissi E, Feng T, Heath AK, Janszky I. Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2023;38:145-78.
  430. Wong TY, Mitchell P. Hypertensive retinopathy. N Engl J Med. 2004;351:2310-7.
  431. Kennelly SP, Lawlor BA, Kenny RA. Blood pressure and dementia - a comprehensive review. Ther Adv Neurol Disord. 2009;2:241-60.
  432. SPS3 Study Group, Benavente OR, Coffey CS, Conwit R, Hart RG, McClure LA, Pearce LA, et al. Blood-pressure targets in patients with recent lacunar stroke: the SPS3 randomised trial. Lancet. 2013;382:507-15.
  433. Bos MJ, Buis S. Thirty-minute office blood pressure monitoring in primary care. Ann Fam Med 2017;15:120-3.
  434. Scherpbier-de Haan N, Van der Wel M, Schoenmakers G, et al. Thirty-minute compared to standardised office blood pressure measurement in general practice. Br J Gen Pract 2011;61:e590-7.
  435. Van der Wel MC, Buunk IE, Van Weel C, et al. A novel approach to office blood pressure measurement: 30-minute office blood pressure versus daytime ambulatory blood pressure. Ann Fam Med 2011;9:128-35.
  436. Culleton BF, McKay DW, Campbell NR. Performance of the automated BpTRU measurement device in the assessment of white-coat hypertension and white-coat effect. Blood Press Monit 2006;11:37-42.
  437. Myers MG, Godwin M, Dawes M, et al. Conventional versus automated measurement of blood pressure in the office (CAMBO) trial. Fam Pract 2012 Aug;29:376-82.
  438. Whelton PK, Carey RM, Aronow WS, et al 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2017;pii:S0735-1097(17)41519-1.
  439. ESH/ESC Task Force for the Management of Arterial Hypertension. 2013 Practice guidelines for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC): ESH/ESC Task Force for the Management of Arterial Hypertension. J Hypertens 2013;31:1925-38.
  440. Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: when, who, and how to screen? Eur Heart J 2014;35:1245-54.
  441. SPRINT Research Group. A randomized trial of intensive versus standard bloodpressure control. N Engl J Med 2015;373:2103-16.
  442. ACCORD Study Group; Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575-85.
  443. Arguedas JA, Leiva V, Wright JM. Blood pressure targets in adults with hypertension. Cochrane Database Syst Rev. 2020;12:CD004349.
  444. Zhang W, Zhang S, Deng Y, Wu S, Ren J, Sun G, et al.; STEP Study Group. Trial of Intensive Blood-Pressure Control in Older Patients with Hypertension. N Engl J Med. 2021;385:1268-79.
  445. SPRINT group, Lewis CE, Fine LJ, Beddhu S, Cheung AK, Cushman WC, Cutler JA, et al. Final report of a trial of intensive versus standard blood-pressure control. New England Journal of Medicine. 2021;384:1921-30.
  446. Cardio-Sis, Verdecchia P, Staessen JA, Angeli F, de Simone G, Achilli A, et al; Cardio-Sis investigators. Usual versus tight control of systolic blood pressure in non-diabetic patients with hypertension (Cardio-Sis): an open-label randomised trial. Lancet. 2009;374:525-33.
  447. Verberk WJ, Kroon AA, Lenders JW, Kessels AG, van Montfrans GA, Smit AJ, et al.; Home Versus Office Measurement, Reduction of Unnecessary Treatment Study Investigators. Self-measurement of blood pressure at home reduces the need for antihypertensive drugs: a randomized, controlled trial. Hypertension. 2007;50:1019-25.
  448. van der Wel MC, Buunk IE, van Weel C, Thien TA, Bakx JC. A novel approach to office blood pressure measurement: 30-minute office blood pressure vs daytime ambulatory blood pressure. Ann Fam Med. 2011;9:128-35.
  449. Filipovský J, Seidlerová J, Kratochvíl Z, Karnosová P, Hronová M, Mayer O Jr. Automated compared to manual office blood pressure and to home blood pressure in hypertensive patients. Blood Press. 2016;25:228-34.
  450. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998;352:1347-51.
  451. Beckett NS, Peters R, Fletcher AE, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008;358:1887-98.
  452. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG): a double-blind, placebo-controlled trial. Lancet neurol 2008;7:683-9.
  453. Staessen JA, Fagard R, Thijs L, et al. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. Arch Intern Med. 1998;158(15):1681-91.
  454. Warwick J, Falaschetti E, Rockwood K, Mitnitski A, Thijs L, Beckett N, et al. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med. 2015;13:78.
  455. Ogihara T, Saruta T, Rakugi H, et al. Target blood pressure for treatment of isolated systolic hypertension in the elderly: valsartan in elderly isolated systolic hypertension study. Hypertension 2010;56:196-202.
  456. Van Bemmel T, Gussekloo J, Westendorp RG, et al. In a population-based prospective study, no association between high blood pressure and mortality after age 85 years. J Hypertens 2006;24:287-92.
  457. Muller M, Jochemsen HM, Visseren FL, et al; SMART-study group. Low blood pressure and antihypertensive treatment are independently associated with physical and mental health status in patients with arterial disease: the SMART study. J Intern Med 2013;274:241-51.
  458. Muller M, Smulders YM, De Leeuw PW, et al. Treatment of hypertension in the oldest old: a critical role for frailty? Hypertension 2014;63:433-41.
  459. Sabayan B, Oleksik AM, Maier AB, et al. High blood pressure and resilience to physical and cognitive decline in the oldest old: the Leiden 85-plus Study. J Am Geriatr Soc. 2012;60(11):2014-9.
  460. Post Hospers G, Smulders YM, Maier AB, et al. Relation between blood pressure and mortality risk in an older population: role of chronological and biological age. High blood pressure and resilience to physical and cognitive decline in the oldest old: the Leiden 85-plus Study. J Am Geriatr Soc 2012;60:2014-9.
  461. McEvoy JW, Chen Y, Rawlings A, et al. Diastolic blood pressure, subclinical myocardial damage, and cardiac events: implications for blood pressure control. J Am Coll Cardiol 2016;68:1713-22.
  462. Messerli FH, Mancia G, Conti CR, et al. Dogma disputed: can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-93.
  463. Franklin SS, Gokhale SS, Chow VH, Larson MG, Levy D, Vasan RS, et al. Does low diastolic blood pressure contribute to the risk of recurrent hypertensive cardiovascular disease events? The Framingham Heart Study. Hypertension. 2015;65:299-305.
  464. Kalkman DN, Brouwer TF, Vehmeijer JT, Berger WR, Knops RE, de Winter RJ, et al. J Curve in Patients Randomly Assigned to Different Systolic Blood Pressure Targets: An Experimental Approach to an Observational Paradigm. Circulation. 2017;136:2220-29.
  465. Casteleijn FM, Golyardi B. Is telemonitoring van hypertensie de toekomst? Huisarts Wet 2022;65.
  466. Saruta T, Ogihara T, Saito I, et al. Comparison of olmesartan combined with a calcium channel blocker or a diuretic in elderly hypertensive patients (COLM Study): safety and tolerability. Hypertens Res. 2015;38(2):132-6.
  467. Ogihara T, Saruta T, Rakugi H, et al. Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial. J Hypertens. 2014;32(10):2054-63; discussion 2063.
  468. Wing LMH, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003;348:583-92.
  469. Benetos A, Consoli S, Safavian A, et al. Efficacy, safety, and effects on quality of life of bisoprolol/hydrochlorothiazide versus amlodipine in elderly patients with systolic hypertension. Am Heart J 2000;140:E11.
  470. Cowley AJ, Wiens BL, Segal R, et al. Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy. Qual Life Res. 2000;9(4):377-84.
  471. Canney M, O’Connell MD, Murphy CM, et al. Single agent antihypertensive therapy and orthostatic blood pressure behaviour in older adults using beat-to-beat measurements: the Irish Longitudinal Study on Ageing. PLoS One 2016;11:e0146156.
  472. Moonen JE, Foster-Dingley JC, De Ruijter W, et al. Effect of Discontinuation of Antihypertensive Treatment in Elderly People on Cognitive Functioning – the DANTE Study Leiden: a randomized clinical trial. JAMA Intern Med 2015;175(10):1622-30.
  473. Huang L, Trieu K, Yoshimura S, Neal B, Woodward M, Campbell NRC, et al. Effect of dose and duration of reduction in dietary sodium on blood pressure levels: systematic review and meta-analysis of randomized trials. BMJ. 2020;368:m315.
  474. Slagman MC, Waanders F, Hemmelder MH, Woittiez AJ, Janssen WM, Lambers Heerspink HJ, et al; HOlland NEphrology STudy Group. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: randomised controlled trial. BMJ. 2011;343:d4366.
  475. Luft FC, Weinberger MH. Review of salt restriction and the response to antihypertensive drugs. Satellite symposium on calcium antagonists. Hypertension. 1988;11:I229-32.
  476. Cook NR, Appel LJ, Whelton PK. Sodium Intake and All-Cause Mortality Over 20 Years in the Trials of Hypertension Prevention. J Am Coll Cardiol. 2016 Oct 11;68(15):1609-1617.
  477. Neal B, Wu Y, Feng X, Zhang R, Zhang Y, Shi J, et al. Effect of Salt Substitution on Cardiovascular Events and Death. N Engl J Med. 2021;385:1067-77.
  478. Temme EHM, Hendriksen MAH, Milder IEJ, Toxopeus IB, Westenbrink S, Brants HAM, et al. Salt Reductions in Some Foods in The Netherlands: Monitoring of Food Composition and Salt Intake. Nutrients. 2017;9:791.
  479. Zanchetti A, Mancia G. Longing for clinical excellence: a critical outlook into the NICE recommendations on hypertension management – is nice always good? J Hypertens 2012;30:660-8.
  480. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016 Mar 5;387:957-67.
  481. Turnbull F, Neal B, Ninomiya T, et al. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ 2008;336:1121-3.
  482. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300.
  483. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet. 2005;366:895-906.
  484. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
  485. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, et al; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008;359:2417-28.
  486. Ojji DB, Mayosi B, Francis V, Badri M, Cornelius V, Smythe W, et al; CREOLE Study Investigators. Comparison of Dual Therapies for Lowering Blood Pressure in Black Africans. N Engl J Med. 2019;380:2429-39.
  487. Achelrod D, Wenzel U, Frey S. Systematic review and meta-analysis of the prevalence of resistant hypertension in treated hypertensive populations. Am J Hypertens. 2015;28:355-61.
  488. Daugherty SL, Powers JD, Magid DJ, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation 2012;125:1635-42.
  489. Durand H, Hayes P, Morrissey EC, Newell J, Casey M, Murphy AW, et al. Medication adherence among patients with apparent treatment-resistant hypertension: systematic review and meta-analysis. J Hypertens. 2017;35:2346-57.
  490. de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898-902.
  491. Simpson SH, Eurich DT, Majumdar SR, et al. A meta-analysis of the association between adherence to drug therapy and mortality. BMJ. 2006;333:15.
  492. Ho PM, Bryson CL, Rumsfeld JS. Medication adherence: its importance in cardiovascular outcomes. Circulation 2009;119:3028-3035.
  493. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97.
  494. Doshi JA, Zhu J, Lee BY, et al. Impact of a prescription copayment increase on lipid-lowering medication adherence in veterans. Circulation 2009;119:390-7.
  495. Gehi A, Haas D, Pipkin S, et al. Depression and medication adherence in outpatients with coronary heart disease: findings from the Heart and Soul Study. Arch Intern Med 2005;165:2508-13.
  496. Tarn DM, Heritage J, Paterniti DA, et al. Physician communication when prescribing new medications. Arch Intern Med 2006;166:1855-62.
  497. Kleppe M, Lacroix J, Ham J, et al. ‘A necessary evil’: associations with taking medication and their relationship with medication adherence. Psychol Health Med 2017;22:1217-23.
  498. Kripalani S, Yao X, Haynes RB. Interventions to enhance medication adherence in chronic medical conditions: a systematic review. The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. Circulation 2010;122:2078-88.
  499. Santschi V, Chiolero A, Burnand B, et al. Impact of pharmacist care in the management of cardiovascular disease risk factors: a systematic review and meta-analysis of randomized trials. Arch Intern Med. 2011;171:1441-1453.
  500. Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart 2001;86:516-21.
  501. Rienstra M, Hobbelt AH, Alings M, et al. Targeted therapy of underlying conditions improves sinus rhythm maintenance in patients with persistent atrial fibrillation: results of the RACE 3 trial. Eur Heart J 2018 Aug 21;39:2987-96.
  502. Nyrnes A, Mathiesen EB, Njolstad I, et al. Palpitations are predictive of future atrial fibrillation. An 11-year follow-up of 22,815 men and women: the Tromso Study. Eur J Prev Cardiol 2013;20:729-36.
  503. Lowres N, Neubeck L, Freedman SB, et al. Lifestyle risk reduction interventions in atrial fibrillation: a systematic review. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group ‘Hypertension Arrhythmias and Thrombosis’ of the European Society of Hypertension. J Hypertens 2012;30:239-52.
  504. Manolis AJ, Rosei EA, Coca A, et al. Hypertension and atrial fibrillation: diagnostic approach, prevention and treatment. Position paper of the Working Group Hypertension Arrhythmias and Thrombosis of the European Society of Hypertension. J Hypertens. 2012;30:239-252.
  505. Kirchhof P, et al. ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 2016;37:2893-62.
  506. Task Force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology (ESC), Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation. Eur Heart J 2012 Oct;33:2569-619.
  507. Hamm CW, Bassand JP, Agewall S, et al; ESC Committee for Practice Guidelines. ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 2011 Dec;32:2999-3054.
  508. Task Force Members, Montalescot G, Sechtem U, Achenbach S; ESC Committee for Practice Guidelines; Document Reviewers, et al. 2013 ESC Guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. Eur Heart J 2013 Oct;34:2949-3003.
  509. Roffi M, Patrono C, Collet JP, Mueller C, Valgimigli M, Andreotti F, Bax JJ, Borger MA, Brotons C, Chew DP, Gencer B, Hasenfuss G, Kjeldsen K, Lancellotti P, Landmesser U, Mehilli J, Mukherjee D, Storey RF, Windecker S; ESC Scientific Document Group . 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J. 2016 Jan 14;37(3):267-315.
  510. Zipes DP, Camm AJ, Borggrefe M, et al; American College of Cardiology/American Heart Association Task Force; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association and the Heart Rhythm Society. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death – executive summary: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Eur Heart J 2006 Sep;27:2099-140.
  511. Kolh P, Windecker S, Alfonso et al.; European Society of Cardiology Committee for Practice Guidelines; Task Force on Myocardial Revascularization of the European Society of Cardiology and the European Association for Cardio-Thoracic Surgery; European Association of Percutaneous Cardiovascular Interventions. 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur J Cardiothorac Surg 2014 Oct;46:517-92.
  512. European Society of Cardiology (ESC); European Heart Rhythm Association (EHRA), Brignole M, Auricchio A, Baron-Esquivias G, et al. 2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA). Europace 2013 Aug;15:1070-118.
  513. Piepoli MF, Corra U, Adamopoulos S, et al. Secondary prevention in the clinical management of patients with cardiovascular diseases. Core components, standards and outcome measures for referral and delivery: a policy statement from the cardiac rehabilitation section of the European Association for Cardiovascular Prevention &#x0026; Rehabilitation. Endorsed by the Committee for Practice Guidelines of the European Society of Cardiology. Eur J Prev Cardiol 2014;21:664-81.
  514. Corra U, Piepoli MF, Carre F, et al. Secondary prevention through cardiac rehabilitation: physical activity counselling and exercise training: key components of the position paper from the Cardiac Rehabilitation Section of the European Association of Cardiovascular Prevention and Rehabilitation. Eur Heart J. 2010;31:1967-1974.
  515. Kotseva K, Wood D, De Backer G, et al. EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil 2009;16:121-37.
  516. Bjarnason-Wehrens B, McGee H, Zwisler AD, et al. Cardiac rehabilitation in Europe: results from the European Cardiac Rehabilitation Inventory Survey. Eur J Cardiovasc Prev Rehabil 2010;17:410-8.
  517. Kotseva K, Wood D, De Backer G, et al. Use and effects of cardiac rehabilitation in patients with coronary heart disease: results from the EUROASPIRE III survey. Eur J Prev Cardiol 2013;20:817-26.
  518. Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 2016 Jan 14;37:267-315.
  519. Jencks SF, Williams MV, Coleman EA. Rehospitalizations among patients in the Medicare fee-for-service program. N Engl J Med 2009;360:1418-28.
  520. Viswanathan M, Golin CE, Jones CD, et al. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med. 2012;157:785-795.
  521. Piepoli MF, Davos C, Francis DP, et al. Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189.
  522. O’Connor CM, Whellan DJ, Lee KL, et al. Efficacy and safety of exercise training in patients with chronic heart failure: HF-ACTION randomized controlled trial. JAMA 2009;301:1439-50.
  523. Piepoli MF, Guazzi M, Boriani G, et al. Exercise intolerance in chronic heart failure: mechanisms and therapies. Part I. Eur J Cardiovasc Prev Rehab. 2010a;17:637-642.
  524. Piepoli MF, Guazzi M, Boriani G, et al. Exercise intolerance in chronic heart failure: mechanisms and therapies. Exercise intolerance in chronic heart failure: mechanisms and therapies. Part II. Eur J Cardiovasc Prev Rehab 2010b;17:643-48.
  525. Conraads VM, Deaton C, Piotrowicz E, et al. Adherence of heart failure patients to exercise: barriers and possible solutions: a position statement of the Study Group on Exercise Training in Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2012;14:451-458.
  526. Mezzani A, Hamm LF, Jones AM, et al. Aerobic exercise intensity assessment and prescription in cardiac rehabilitation: a joint position statement of the European Association for Cardiovascular Prevention and Rehabilitation, the American Association of Cardiovascular and Pulmonary Rehabilitation and the Canadian Association of Cardiac Rehabilitation. Eur J Prev Cardiol 2013;20:442-467.
  527. Haykowsky MJ, Timmons MP, Kruger C, et al. Meta-analysis of aerobic interval training on exercise capacity and systolic function in patients with heart failure and reduced ejection fractions. Am J Cardiol 2013;111:1466-9.
  528. Wisloff U, Stoylen A, Loennechen JP, et al. Superior cardiovascular effect of aerobic interval training versus moderate continuous training in heart failure patients: a randomized study. Circulation 2007;115:3086-94.
  529. Piepoli MF, Conraads V, Corra U, et al. Exercise training in heart failure: from theory to practice. A consensus document of the Heart Failure Association and the European Association for Cardiovascular Prevention and Rehabilitation. Eur J Heart Fail 2011;13:347-57.
  530. Mohan KM, Wolfe CD, Rudd AG, et al. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke. 2011;42(5):1489-94.
  531. Van Wijk I, Kappelle LJ, Van Gijn J, et al. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: A cohort study. Lancet 2005;365:2098-104.
  532. Johnston SC, Rothwell PM, Nguyen-Huynh MN, et al. Validation and refinement of scores to predict very early stroke risk after transient ischaemic attack. Lancet 2007;369:283-92.
  533. Lennon O, Galvin R, Smith K, et al. Lifestyle interventions for secondary disease prevention in stroke and transient ischaemic attack: a systematic review. Eur J Prev Cardiol 2014;21:1026-39.
  534. Collins R, Armitage J, Parish S, et al. Heart Protection Study Collaborative Group. Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet 2004;363:757-67.
  535. Amarenco P, Bogousslavsky J, Callahan A 3rd, et al. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med 2006;355:549-59.
  536. Hackam DG, Woodward M, Newby LK, et al. Statins and intracerebral hemorrhage: collaborative systematic review and meta-analysis. Circulation 2011;124:2233-42.
  537. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-236.
  538. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41.
  539. Arima H, Chalmers J, Woodward M, et al. Lower target blood pressures are safe and effective for the prevention of recurrent stroke: the PROGRESS trial. J Hypertens 2006;24:1201-8.
  540. Arima H, Anderson C, Omae T, et al. Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial. J Neurol Neurosurg Psychiatry 2014;85:1284-5.
  541. ESPRIT Study Group, Halkes PH, Van Gijn J, et al. Aspirin plus dipyridamole versus aspirin alone after cerebral ischaemia of arterial origin (ESPRIT): randomised controlled trial. Lancet 2006;367:1665-73.
  542. Sacco RL, Diener HC, Yusuf S, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. N Engl J Med 2008;359:1238-51.
  543. Banerjee A. A review of family history of cardiovascular disease: risk factor and research tool. Int J Clin Pract 2012;66:536-43.
  544. Emerging Risk Factors Collaboration, Di Angelantonio E, Sarwar N, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302:1993-2000.
  545. Wilson PW, Pencina M, Jacques P, et al. C-reactive protein and reclassification of cardiovascular risk in the Framingham Heart Study. Circ Cardiovasc Qual Outcomes 2008;1:92-97.
  546. Ioannidis JP. Prediction of cardiovascular disease outcomes and established cardiovascular risk factors by genome-wide association markers. Circ Cardiovasc Genet. 2009;2:7-15.
  547. CAPRIE Steering Committee. A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. Lancet 1996 Nov 16;348:1329-39.
  548. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-60.
  549. Ikeda Y, Shimada K, Teramoto T, et al. Low-dose aspirin for primary. JAMA 2014;312: 2510-20.
  550. Bhatt DL, Fox KA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-17.
  551. Silagy CA, McNeil JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther. 1993;54(1):84-9.
  552. Sivenius J, Cunha L, Diener HC, Foet al. Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group. Acta Neurol Scand. 1999;99(1):54-60.
  553. Jorgensen T, Capewell S, Prescott E, et al. Population-level changes to promote cardiovascular health. Eur J Prev Cardiol 2013;20:409-21.
  554. National Institute for Health and Care Excellence. Prevention of cardiovascular disease at the population level. London: National Institute for Health and Care Excellence, 2010.
  555. Capewell S, O’Flaherty M. Rapid mortality falls after risk-factor changes in populations. Lancet 2011;378:752-3
  556. EU platform on diet, physical activity and health. European Union, 2005. Ga naar bron
  557. Hawkes C, Smith TG, Jewell J, et al. Smart food policies for obesity prevention. Lancet 2015;385:2410-21.
  558. Bureau Europeén des Unions de Consommateurs. The consumer case for EU legal restrictions on the use of artificial trans-fats in food. Position paper. Brussels: European Union, 2014. Ga naar bron
  559. He FJ, Pombo-Rodrigues S, Macgregor GA. Salt reduction in England from 2003 to 2011: its relationship to blood pressure, stroke and ischaemic heart disease mortality. BMJ Open 2014;4:e004549.
  560. Hendriksen M. et al. Zout-, jodium- en kaliuminname 2015. Voedingsstatusonderzoek bij volwassenen uit Doetinchem. Association between alcohol and cardiovascular disease: Mendelian randomisation analysis based on individual participant data. BMJ 2014 Jul 10;349:g4164.
  561. Rijksoverheid. Akkoord verbetering productsamenstelling, 2014 Ga naar bron
  562. Hoogendoorn MP, Van den Berg M. Rijksinstituut voor Volksgezondheid en Milieu. De waarde van voedselkeuzelogo voor het voedingsbeleid. Advies van de Onafhankelijke Commissie Voedselkeuzelogo. 2016, aangepast in 2017.
  563. Wanders AJ, Brouwer IA, Siebelink E, et al. Effect of a high intake of conjugated linoleic acid on lipoprotein levels in healthy human subjects. PLoS ONE 2010;5:e9000.
  564. Collard D, Slot-Heijs J, Dellas V, Van der Poel H. Monitor jongeren op gezond gewicht 2017. Mulier instituut, 2018 Ga naar bron
  565. Romon M, Lommez A, Tafflet M, et al. Downward trends in the prevalence of childhood overweight in the setting of 12-year school- and community-based programmes. Public Health Nutrition. 2009;12(10):1735-1742. doi:10.1017/S1368980008004278
  566. Veerman JL, Van Beeck EF, Barendregt JJ, et al. By how much would limiting TV food advertising reduce childhood obesity? Eur J Public Health 2009;19:365-9.
  567. Wakefield MA, Loken B, Hornik RC. Use of mass media campaigns to change health behaviour. Lancet 2010;376:1261-71.
  568. Grunert KG, Wills JM. A review of European research on consumer response to nutrition information on food labels. J Public Health 2007;15:385-99.
  569. Wilson-van den Hooven et al. Rijksinstituut voor Volksgezondheid en Milieu. Naar een integraal systeem voor productverbetering in Nederland: Advies van de Commissie Criteria Productverbetering, 2018.
  570. European Heart Network. Diet, physical activity and cardiovascular disease prevention in Europe. Brussels: European Heart Network, 2011.
  571. Consumentenbond. Consumentenonderzoek voedselkeuzelogo’s, april 2018
  572. Eyles H, Ni Mhurchu C, Nghiem N, et al. Food pricing strategies, population diets, and non-communicable disease: a systematic review of simulation studies. PLoS Med 2012;9:e1001353.
  573. Powell LM, Chriqui JF, Khan T, et al. Assessing the potential effectiveness of food and beverage taxes and subsidies for improving public health: a systematic review of prices, demand and body weight outcomes. Obesity Rev 2013;14:110-28.
  574. World Health Organization. Fiscal policies for diet and prevention of noncommunicable diseases: technical meeting report, 5-6 May 2015, Geneva: WHO, 2016.
  575. Gezonde School. geraadpleegd juni 2018. Ga naar bron
  576. Geaney F, Kelly C, Greiner BA, et al. The effectiveness of workplace dietary modification interventions: a systematic review. Prev Med 2013;57:438-47.
  577. Lollgen H, Bockenhoff A, Knapp G. Physical activity and all-cause mortality: an updated meta-analysis with different intensity categories. Int J Sports Med 2009;30:213-24.
  578. American College of Sports Medicine. ACSM’s guidelines for exercise testing and prescription. 9th ed. Baltimore: Wolters Kluwer/Lippincott, 2014.
  579. Global Advocacy Council for Physical Activity, International Society for Physical Activity and Health. The Toronto Charter for Physical Activity: a global call for action. J Physical Activity Health 2010;7(Suppl 3):S370-85.
  580. Rijksoverheid. Geraadpleegd juni 2018. Ga naar bron
  581. Huhman ME, Potter LD, Duke JC, et al. Evaluation of a national physical activity intervention for children: VERB campaign, 2002 to 2004. Am J Prev Med 2007;32:38-43.
  582. EFSMA Ga naar bron
  583. Kerr J, Eves F, Carroll D. Six-month observational study of prompted stair climbing. Prev Med 2001;33:422-7.
  584. Hartstichting. geraadpleegd juni 2018. Ga naar bron
  585. NISB. Geraadpleegd juni 2018. Ga naar bron
  586. Mozaffarian D, Afshin A, Benowitz NL, et al. Population approaches to improve diet, physical activity, and smoking habits: a scientific statement from the American Heart Association. Circulation 2012;126:1514-63.
  587. Kriemler S, Zahner L, Schindler C, et al. Effect of school based physical activity programme (KISS) on fitness and adiposity in primary schoolchildren: cluster randomised controlled trial. BMJ 2010;340:c785.
  588. Hillman CH, Pontifex MB, Castelli DM, et al. Effects of the FITKids randomized controlled trial on executive control and brain function. Pediatrics 2014;134:e1063-71.
  589. Colcombe SJ, Kramer AF, Erickson KI, et al. Cardiovascular fitness, cortical plasticity, and aging. Proc Natl Acad Sci USA 2004;101:3316-21.
  590. Mendoza JA, Levinger DD, Johnston BD. Pilot evaluation of a walking school bus program in a low-income, urban community. BMC Public Health 2009;9:122.
  591. Richtlijnen voor bewegingsonderwijs van basisschool tot mbo. Geraadpleegd juni 2018. Ga naar bron
  592. Leyk D, Rohde U, Hartmann ND, et al. Results of a workplace health campaign: what can be achieved? Dtsch Arztebl Int 2014;111:320-7.
  593. World Health Organization. Guidelines for implementation. WHO Framework Convention on Tobacco Control. Articles 5.3, 8-14. Geneva: World Health Organization, 2011.
  594. Iversen B, Jacobsen BK, Lochen ML. Active and passive smoking and the risk of myocardial infarction in 24,968 men and women during 11 year of follow-up: the Tromso Study. Eur J Epidemiol. 2013;28:659-667.
  595. Arefalk G, Hambraeus K, Lind L, et al. Discontinuation of smokeless tobacco and mortality risk after myocardial infarction. Circulation 2014;130:325-32.
  596. International Agency for Research on Cancer. Monographs on the evaluation of carcinogenic risks to humans. Volume 100E. Personal Habits and Indoor Combustions. Smokeless Tabacco. 2012 Ga naar bron
  597. Gallefoss F, Holmen T, Grimsrud T, et al. Snus under svangerskap er ikke ufarlig. Tidsskrift for Den norske legeforening. 2012;132:932-933.
  598. Rijksinstituut voor Volksgezondheid en Milieu. E-sigaret aantrekkelijkheid voor rokers en niet-rokers (2018). Ga naar bron
  599. Lochen ML, Gram IT, Skattebo S, et al. Tobacco images and texts in Norwegian magazines and newspapers. Scand J Public Health 2007;35:31-8.
  600. Rookvrijegeneratie. Geraadpleegd juni 2018. Ga naar bron
  601. Ketelaars T, Croes E. Effecten van accijns en prijs op het gebruik van tabaksproducten. Utrecht: Trimbos-instituut, 2015
  602. Leefstijlmonitor, 2017. Geraadpleegd op 2-7-2018. Ga naar bron
  603. World Health Organization. Global status report on alcohol and health. Ga naar bron
  604. Brien SE, Ronksley PE, Turner BJ, et al. Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ 2011;342:d636.
  605. Mukamal KJ, Chen CM, Rao SR, et al. Alcohol consumption and cardiovascular mortality among U.S. adults, 1987 to 2002. J Am Coll Cardiol 2010;55:1328-35.
  606. Klatsky AL. Alcohol and cardiovascular mortality: common sense and scientific truth. J Am Coll Cardiol 2010;55:1336-8.
  607. Britton A , McKee M. The relation between alcohol and cardiovascular disease in Eastern Europe: explaining the paradox. J Epidemiol Community Health. 2000;54:328-332.
  608. Anderson P. Global alcohol policy and the alcohol industry. Curr Opin Psychiatry 2009;22:253-7.
  609. Wagenaar AC, Salois MJ, Komro KA. Effects of beverage alcohol price and tax levels on drinking: a meta-analysis of 1003 estimates from 112 studies. Addiction 2009;104:179-90.
  610. National Institute for Health and Care Excellence. Alcohol-use disorders: preventing the development of hazardous and harmful drinking. Ga naar bron
  611. Her M, Giesbrecht N, Room R, et al. Privatizing alcohol sales and alcohol consumption: evidence and implications. Addiction 1999;94:1125-39.
  612. Mann RE, Macdonald S, Stoduto LG, et al. The effects of introducing or lowering legal per se blood alcohol limits for driving: an international review. Accid Anal Prev 2001;33:569-83.
  613. Stockwell T. A review of research into the impacts of alcohol warning labels on attitudes and behaviour. British Colombia, Canada: Center for Addiction Research of BC, University of Victoria, 2006.
  614. Trimbos Instituut. Geraadpleegd juni 2018. Ga naar bron
  615. Kaner EF, Beyer F, Dickinson HO, et al. Effectiveness of brief alcohol interventions in primary care populations. Cochrane Database Syst Rev 2007;2:CD004148.
  616. Newby DE, Mannucci PM, Tell GS, et al. Expert position paper on air pollution and cardiovascular disease. Eur Heart J 2015;36:83-93b.
  617. Rutledge-Jonker S, Berkhout JPJ, Wesseling JP et al. Monitoringsrapportage NSL 2017: Stand van zaken Nationaal Samenwerkingsprogramma Luchtkwaliteit. Bilthoven: RIVM, 2017.
  618. EU. Richtlijn Nationale Emissieplafonds en Pakket Luchtkwaliteit (2016). Ga naar bron
  619. Tweede Kamer. Motie_van_het_lid_Van_Veldhoven_c.s._over_een_nationaal_luchtplan, 2016. Ga naar bron
  620. Milieudefensie. Geraadpleegd juni 2018. Ga naar bron
  621. Boomsma LJ, Van de Vijver PP, Lanphen JMG, et al. Landelijk Transmurale Afspraak Cardiovasculair Risicomanagement. NHG, NVVC, NIV, NVvN, NVvV. 2016. Ga naar bron
  622. Ineen. Rapport transparante Ketenzorg 2017. Utrecht: Ineen, 2018.
  623. Murphy AW, Cupples ME, Smith SM, et al. Effect of tailored practice and patient care plans on secondary prevention of heart disease in general practice: cluster randomised controlled trial. BMJ 2009;339:b4220.
  624. Wood DA, Kotseva K, Connolly S, et al. Nurse-coordinated multidisciplinary, family-based cardiovascular disease prevention programme (EUROACTION) for patients with coronary heart disease and asymptomatic individuals at high risk of cardiovascular disease: a paired, cluster-randomised controlled trial. Lancet 2008;371:1999-2012.
  625. Voogdt-Pruis HR, Beusmans GH, Gorgels AP, et al. Effectiveness of nurse-delivered cardiovascular risk management in primary care: a randomised trial. Br J Gen Pract 2010;60:40-6.
  626. Allen JK, Dennison-Himmelfarb CR, Szanton SL, et al. Community Outreach and Cardiovascular Health (COACH) Trial: a randomized, controlled trial of nurse practitioner/community health worker cardiovascular disease risk reduction in urban community health centers. Circ Cardiovasc Qual Outcomes 2011;4:595-602.
  627. Koopmans B, Korevaar J, Nielen M, et al. NIVEL Overzichtsstudies: preventie kan effectiever! Deelnamebereidheid en deelnametrouw aan preventieprogramma’s in de zorg. Utrecht: NIVEL, 2012.
  628. Andrikopoulos G, Tzeis S, Nikas N, et al. Short-term outcome and attainment of secondary prevention goals in patients with acute coronary syndrome – results from the countrywide TARGET study. Int J Cardiol 2013;168:922-7.
  629. Anderson L, Taylor RS. Cardiac rehabilitation for people with heart disease: an overview of Cochrane systematic reviews. Cochrane Database Syst Rev 2014;12:CD011273.
  630. Clark RA, Conway A, Poulsen V, et al. Alternative models of cardiac rehabilitation: a systematic review. Eur J Prev Cardiol 2015;22:35-74.
  631. Karmali KN, Davies P, Taylor F, et al. Promoting patient uptake and adherence in cardiac rehabilitation. Cochrane Database Syst Rev 2014;6:CD007131.
  632. Gravely-Witte S, Leung YW, Nariani R, et al. Effects of cardiac rehabilitation referral strategies on referral and enrollment rates. Nat Rev Cardiol 2010;7:87-96.
  633. Jorstad HT, Von Birgelen C, Alings AM, et al. Effect of a nurse-coordinated prevention programme on cardiovascular risk after an acute coronary syndrome: main results of the RESPONSE randomised trial. Heart 2013;99:1421-30.
  634. Taylor RS, Dalal H, Jolly K, et al. Home-based versus centre-based cardiac rehabilitation. Cochrane Database Syst Rev 2010;1:CD007130.
  635. Neubeck L, Redfern J, Fernandez R, et al. Telehealth interventions for the secondary prevention of coronary heart disease: a systematic review. Eur J Cardiovasc Prev Rehabil 2009;16:281-9.
  636. Piotrowicz E, Korzeniowska-Kubacka I, Chrapowicka A, et al. Feasibility of home-based cardiac telerehabilitation: results of TeleInterMed study. Cardiol J 2014;21:539-46.
  637. Varnfield M, Karunanithi M, Lee CK, et al. Smartphone-based home care model improved use of cardiac rehabilitation in postmyocardial infarction patients: results from a randomised controlled trial. Heart 2014;100:1770-9.
  638. Van Dis I, Strijbis AM, Spreeuwenberg C. Vijf jaar cardiovasculair risicomanagement in Nederland: the state of the art. Den Haag: Hartstichting, 2014.
  639. Coördinatieplatform Zorgstandaarden. Factsheet. Ontwikkeling generiek individueel zorgplan. NHG, Vilans, NPCF, ZonMw. 2014. Ga naar bron
  640. Platform Vitale Vaten. Zorgstandaard cardiovasculair risicomanagement voor zorgverleners. 2013 Ga naar bron
  641. De Hart&Vaatgroep. Kwaliteitscriteria cardiovasculair risicomanagement. Den Haag: De Hart&Vaatgroep, 2013.
  642. Multidisciplinaire richtlijn Hartrevalidatie. Revalidatiecommissie van de Nederlandse Vereniging Voor Cardiologie/Nederlandse Hartstichting (Richtlijn Hartrevalidatie 2004), Projectgroep PAAHR (gedeeltelijke herziening 2011).
  643. Nederlandse Vereniging voor Neurologie, Richtlijn Beroerte, 2008. Ga naar bron
  644. Nederlandse Vereniging voor Heelkunde, Richtlijn Perifeer Arterieel Vaatlijden, 2016. Ga naar bron
  645. KNMG. Verantwoordelijkheidsdeling bij samenwerking in de zorg. 2010. Ga naar bron
  646. Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Rev Esp Cardiol (Engl Ed) 2018 Feb;71:111.
  647. Bansal N, Fischbacher CM, Bhopal RS, et al. Myocardial infarction incidence and survival by ethnic group: Scottish Health and Ethnicity Linkage retrospective cohort study. Ethnic variations in the incidence and mortality of stroke in the Scottish Health and Ethnicity Linkage Study of 4.65 million people. Eur J Prev Cardiol 2012;19:1503-8.
  648. Bhopal RS, Humphry RW, Fischbacher CM. Changes in cardiovascular risk factors in relation to increasing ethnic inequalities in cardiovascular mortality: comparison of cross-sectional data in the Health Surveys for England 1999 and 2004. Predicted and observed cardiovascular disease in South Asians: application of FINRISK, Framingham and SCORE models to Newcastle Heart Project data. J Public Health 2005;27:93-100.
  649. Bonamy AK, Parikh NI, Cnattingius S, et al. Birth characteristics and subsequent risks of maternal cardiovascular disease: effects of gestational age and fetal growth. Circulation 2011;124:2839-46.
  650. Boomsma LJ, Van de Vijver PP, Lanphen JMG, et al. Landelijke Transmurale Afspraak Cardiovasculair Risicomanagement. 2015. Ga naar bron
  651. Britton A, McKee M. The relation between alcohol and cardiovascular disease in Eastern Europe: explaining the paradox. The consumer case for EU legal restrictions on the use of artificial trans-fats in food. Position paper. Brussels: European Union, 2014. Ga naar bron
  652. Burke AP, Kolodgie FD, Farb A, et al. Morphological predictors of arterial remodeling in coronary atherosclerosis. Prevalence, vascular distribution, and multiterritorial extent of subclinical atherosclerosis in a middle-aged cohort: the PESA (Progression of Early Subclinical Atherosclerosis) study. Circulation 2015;131:2104-13.
  653. Byrne D, O’Connor L, Jennings S, et al. A survey of GPs awareness and use of risk assessment tools and cardiovascular disease prevention guidelines. Irish Med J 2015;108:204-7.
  654. Castellano JM, Sanz G, Penalvo JL, et al. A polypill strategy to improve adherence: results from the FOCUS project. J Am Coll Cardiol 2014;64: 2071-82.
  655. Dallongeville J, Banegas JR, Tubach F, et al. Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA study. Eur J Prev Cardiol 2012;19:541-50.
  656. De Cates AN, Farr MR, Wright N, et al. Fixed-dose combination therapy for the prevention of cardiovascular disease. Cochrane Database Syst Rev 2014;4:CD009868.
  657. Edwards A, Elwyn G. Shared decision-making in health care. Achieving evidence-based patient choice. Second Edition. Oxford: Oxford University Press, 2012.
  658. Emberson JR, Kearney PM, Blackwell L, et al. Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol 2004 Jun 15;93:1481-6.
  659. Fan Z, Wu Y, Shen J, et al. Schizophrenia and the risk of cardiovascular diseases: a meta-analysis of thirteen cohort studies. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000;342:1077-84.
  660. Gezondheidsraad. Beweegrichtlijnen 2017. Den Haag: Gezondheidsraad, 2017; publicatienr. 2017/08.
  661. Giannuzzi P, Temporelli PL, Marchioli R, et al. Global secondary prevention strategies to limit event recurrence after myocardial infarction: results of the GOSPEL study, a multicenter, randomized controlled trial from the Italian Cardiac Rehabilitation Network. Arch Intern Med 2008;168:2194-204.
  662. Giugliano RP, Pedersen TR, Park JG, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet 2017;390:1962-71.
  663. Gulliksson M, Burell G, Vessby B, et al. Randomized controlled trial of cognitive behavioral therapy versus standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: Secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Collaborative care for depression and anxiety disorders in patients with recent cardiac events: the Management of Sadness and Anxiety in Cardiology (MOSAIC) randomized clinical trial. JAMA Intern Med 2014a;174:927-35.
  664. Handreiking Verantwoordelijkheidsverdeling KNMG 2010. 2010. Ga naar bron
  665. Hartstichting. Ga naar bron
  666. Hecht HS, Superko HR. Electron beam tomography and National Cholesterol Education Program guidelines in asymptomatic women. J Am Coll Cardiol 2001;37:1506-11.
  667. Hempler NF, Diderichsen F, Larsen FB, et al. Do immigrants from Turkey, Pakistan and Yugoslavia receive adequate medical treatment with beta-blockers and statins after acute myocardial infarction compared with Danishborn residents? A register-based follow-up study. Eur J Clin Pharmacol 2010;66:735-42.
  668. Hoffmann U, Massaro JM, D’Agostino RB, et al. Cardiovascular event prediction and risk reclassification by coronary, aortic and valvular calcification in the Framingham Heart Study. Clinical characteristics of patients with obstructive coronary lesions in the absence of coronary calcification: an evaluation by coronary CT angiography. Heart 2009;95:1056-60.
  669. Implementation of Spanish adaptation of the European guidelines on cardiovascular disease prevention in primary care. BMC Fam Pract 2013;14:36.
  670. Ioannidis JP, Tzoulaki I. Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease. Long term mortality of mothers and fathers after pre-eclampsia: population-based cohort study. BMJ 2001;323:1213-7.
  671. Kociol RD, McNulty SE, Hernandez AF, et al. Markers of decongestion, dyspnea relief, and clinical outcomes among patients hospitalized with acute heart failure. Circ Heart Fail 2013;6:240-5.
  672. Jørgensen PG, Jensen JS, Marott JL, et al. Electrocardiographic changes improve risk prediction in asymptomatic persons age 65 years or above without cardiovascular disease. J Am Coll Cardiol 2014;2:64:898-906.
  673. Kotseva K, Wood D, De Backer G, et al. Management of cardiovascular risk factors in asymptomatic high-risk patients in general practice: cross-sectional survey in 12 European countries. Eur J Cardiovasc Prev Rehabil 2010;17:530-40.
  674. Lagro-Jansen T, Keijsers K, Olde Rikkert M. Stap voor stap samen beslissen. Med Contact 2014. Ga naar bron
  675. Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002;360:1903-13.
  676. Liu SC, Xia L, Zhang J, et al. Gout and risk of myocardial infarction: a systematic review and meta-analysis of cohort studies. PLoS One 2015;10:e0134088.
  677. Longfonds. Geraadpleegd juni 2018. Ga naar bron
  678. Mancia G, Facchetti R, Bombelli M, et al. Long-term risk of mortality associated with selective and combined elevation in office, home, and ambulatory blood pressure. Hypertension 2006;47:846-53.
  679. Matsushita K, Mahmoodi BK, Woodward M, et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012;307:1941-51.
  680. MDR Herseninfarct/-bloeding. Werkgroep MDR Herseninfarct/-bloeding. 2017. Ga naar bron
  681. Montorsi P, Ravagnani PM, Galli S, et al. Association between erectile dysfunction and coronary artery disease: matching the right target with the right test in the right patient. Eur Urol 2006;50:721-31.
  682. Morgan CL, Jenkins-Jones S, Currie CJ, et al. Evaluation of adverse outcome in young women with polycystic ovary syndrome versus matched, reference controls: a retrospective, observational study. Outbursts of anger as a trigger of acute cardiovascular events: a systematic review and meta-analysis. Eur Heart J 2014;35:1404-10.
  683. Muller I, Seyfarth M, Rudiger S, et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart (British Cardiac Society) 2001;85:92-3.
  684. Myers MG, Godwin M, Dawes M, et al. Measurement of blood pressure in the office: recognizing the problem and proposing the solution. Hypertension 2010;55:195-200.
  685. Neaton JD, Wentworth D. Serum cholesterol, blood pressure, cigarette smoking, and death from coronary heart disease. Overall findings and differences by age for 316,099 white men. Multiple Risk Factor Intervention Trial Research Group. Blood pressure measuring devices: recommendations of the European Society of Hypertension. BMJ 2001; 322:531-6.
  686. Neaton JD, Blackburn H, Jacobs D, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Multiple Risk Factor Intervention Trial Research Group. Arch Intern Med. 1992;152:1490–1500.
  687. O’Rourke MF, Adji A. Guidelines on guidelines: focus on isolated systolic hypertension in youth. J Hypertens 2013;31:649-54.
  688. Orth-Gomer K, Schneiderman N, Wang HX, et al. Stress reduction prolongs life in women with coronary disease: the Stockholm Women’s Intervention Trial for Coronary Heart Disease (SWITCHD). Circ Cardiovasc Qual Outcomes 2009;2:25-32.
  689. Parati G, Stergiou GS, Asmar R, et al. European Society of Hypertension guidelines for blood pressure monitoring at home: a summary report of the Second International Consensus Conference on Home Blood Pressure Monitoring. J Hypertens 2008;26:1505-26.
  690. Pascual JM, Rodilla E, Costa JA, et al. Prognostic value of microalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 2014;64:1228-34.
  691. Patiëntenfederatie Nederland, Federatie Medisch Specialisten. Drie goede vragen. 2018. Ga naar bron
  692. Pencina MJ, D’Agostino RB Sr, D’Agostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 2008 Jan 30;27:157-72; discussion 207-12.
  693. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European guidelines on cardiovascular disease prevention in clinical practice. The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts. Developed with the special contribution of the European Association for Cardiovascular Prevention &#x0026; Rehabilitation). G Ital Cardiol (Rome) 2017;18:547-612.
  694. Ponikowski P, Voors AA, Anker SD, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014;4:CD003331.
  695. Preis SR, Hwang SJ, Coady S, et al. Trends in all-cause and cardiovascular disease mortality among women and men with and without diabetes mellitus in the Framingham Heart Study, 1950 to 2005. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) the European Atherosclerosis Society (EAS). Eur Heart J 2011;32:1769-818.
  696. Raad voor de Volksgezondheid &#x0026; Zorg. De participerende patiënt. Den Haag: RVZ, 2013.
  697. Raza Q, Snijder MB, Seidell JC, et al. Comparison of cardiovascular risk factors and dietary intakes among Javanese Surinamese and South-Asian Surinamese in the Netherlands. Heterogeneity in cause-specific mortality according to birthplace in immigrant men residing in Madrid, Spain. Ann Epidemiol 2008;18:605-13.
  698. Reiner Z, Sonicki Z, Tedeschi-Reiner E. Physicians’ perception, knowledge and awareness of cardiovascular risk factors and adherence to prevention guidelines: the PERCRO-DOC survey. Atherosclerosis 2010;213:598-603.
  699. RIVM Leefstijlmonitor. Zoekterm leefstijlmonitor. Geraadpleegd 7 december 2017. Ga naar bron
  700. Rogers PJ, Hogenkamp PS, De Graaf C et al. Does low-energy sweetener consumption affect energy intake and body weight? A systematic review, including meta-analyses, of the evidence from human and animal studies. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011;342:d671.
  701. Schottker B, Jorde R, Peasey A, et al. Vitamin D and mortality: meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ 2014;348:g3656.
  702. Sehestedt T, Jeppesen J, Hansen TW, et al. Risk prediction is improved by adding markers of subclinical organ damage to SCORE. Eur Heart J 2010;31:883-91.
  703. Senni M, Paulus WJ, Gavazzi A, et al. New strategies for heart failure with preserved ejection fraction: the importance of targeted therapies for heart failure phenotypes. Eur Heart J 2014;35:2797-815.
  704. Silagy CA, McNeil JJ, Donnan GA, et al. Adverse effects of low-dose aspirin in a healthy elderly population. Second European Stroke Prevention Study: antiplatelet therapy is effective regardless of age. ESPS2 Working Group. Acta Neurol Scand 1999;99:54-60.
  705. Somers VK, White DP, Amin R, et al. Sleep apnea and cardiovascular disease: an American Heart Association/American College of Cardiology Foundation Scientific Statement from the American Heart Association Council for High Blood Pressure Research Professional Education Committee, Council on Clinical Cardiology, Stroke Council, and Council on Cardiovascular Nursing. In collaboration with the National Heart, Lung, and Blood Institute National Center on Sleep Disorders Research (National Institutes of Health). Circulation 2008;118:1080-111.
  706. Staessen JA, Fagard R, Thijs L, et al. Subgroup and per-protocol analysis of the randomized European Trial on Isolated Systolic Hypertension in the Elderly. No evidence that frailty modifies the positive impact of antihypertensive treatment in very elderly people: an investigation of the impact of frailty upon treatment effect in the HYpertension in the Very Elderly Trial (HYVET) study, a double-blind, placebo-controlled study of antihypertensives in people with hypertension aged 80 and over. BMC Med 2015;13:78.
  707. Stam-Slob MC, Van der Graaf Y, De Boer A, et al. Cost-effectiveness of PCSK9 inhibition in addition to standard lipid-lowering therapy in patients at high risk for vascular disease. Int J Cardiol 2018;253:148-154.
  708. Stewart JC, Perkins AJ, Callahan CM. Effect of collaborative care for depression on risk of cardiovascular events: data from the IMPACT randomized controlled trial. Employee effects of an educational program for managers at an insurance company. Psychosom Med 2001;63:724-33.
  709. Taylor RS, Sagar VA, Davies EJ, et al. Exercise-based rehabilitation for heart failure. Cochrane Database Syst Rev 2014;4:CD003331.
  710. Tran AT, Straand J, Diep LM, et al. Cardiovascular disease by diabetes status in five ethnic minority groups compared to ethnic Norwegians. BMC Public Health 2011;11:554.
  711. U.S. Preventive Services Task Force. Screening for peripheral arterial disease: recommendation statement. Am Fam Physician 2006;73:497-500.
  712. Udelson JE. Heart failure with preserved ejection fraction. Interventions to improve adherence to self-administered medications for chronic diseases in the United States: a systematic review. Ann Intern Med 2012;157:785-95.
  713. Valgimigli M, Costa F, Byrne R, et al. Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey EuroIntervention 2015;11:68-74.
  714. Vlachopoulos C, Jackson G, Stefanadis C, et al. Erectile dysfunction in the cardiovascular patient. Eur Heart J 2013a;34:2034-46.
  715. Vlachopoulos CV, Terentes-Printzios DG, Ioakeimidis NK, et al. Prediction of cardiovascular events and all-cause mortality with erectile dysfunction: a systematic review and meta-analysis of cohort studies. Circ Cardiovasc Qual Outcomes 2013b;6:99-109.
  716. Wachtell K, Okin PM, Olsen MH, et al. Regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy and reduction in sudden cardiac death: the LIFE Study. Circulation 2007;116:700-5.
  717. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003;326:1419.
  718. Williams B, MacDonald TM, Morant S, et al.; British Hypertension Society’s PATHWAY Studies Group. Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015 Nov 21;386:2059-68.
  719. Woodward M, Hirakawa Y, Kengne AP, et al. ADVANCE Collaborative Group. Prediction of 10-year vascular risk in patients with diabetes: the AD-ON risk score. Metabolite profiling and cardiovascular event risk: a prospective study of 3 population-based cohorts. Circulation 2015;131:774-85.
  720. World Health Organisation. WHO Global Health Repository. Cardiovascular diseases, deaths per 100 000. Data by country.
  721. Yancy CW, Jessup M, Bozkurt B, et al. ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2013;128: e240-327.
  722. Zhang Z, Xu G, Liu D, et al. Dietary fiber consumption and risk of stroke. Fish consumption and CHD mortality: an updated meta-analysis of seventeen cohort studies. Public Health Nutr 2012;15:725-37.
  723. Zorgstandaard CVRM. 2013 Ga naar bron
  724. Bhopal RS, Bansal N, Fischbacher CM, Brown H, Capewell S; Scottish Health and Ethnic Linkage Study. Ethnic variations in the incidence and mortality of stroke in the Scottish Health and Ethnicity Linkage Study of 4.65 million people. Eur J Prev Cardiol. 2012;19:1503-8.
  725. Nissen SE, Menon V, Nicholls SJ, Brennan D, Laffin L, Ridker P,et al. Bempedoic Acid for Primary Prevention of Cardiovascular Events in Statin-Intolerant Patients. JAMA. 2023;330:131-140.
  726. Wei L, MacDonald TM, Watson AD, Murphy MJ. Effectiveness of two statin prescribing strategies with respect to adherence and cardiovascular outcomes: observational study. Pharmacoepidemiol Drug Saf. 2007;16:385-92.
  727. Nußbaumer B, Glechner A, Kaminski-Hartenthaler A, et al. Ezetimibe-Statin Combination Therapy. Dtsch Arztebl Int 2016;113:445-53
  728. Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010;69:325-31.
  729. Gijsberts CM, Groenewegen KA, Hoefer IE, et al. Race/ethnic differences in the associations of the Framingham risk factors with carotid IMT and cardiovascular events. PLoS One 2015 2;10:e0132321.
  730. Lim SS, Vos T, Flaxman AD, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990 tot 2010: a systematic analysis for the Global Burden of Disease Study 2010. Differential impact of systolic and diastolic blood pressure level on JNC-VI staging. Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 1999;34:381-5.
Enkel-armindex
30 gerelateerde lacunes14 gerelateerde onderzoeken
E-mail